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DNA excision repair pathways, including the nucleotide excision repair 
(NER) and the base excision repair (BER) pathways, play significant roles in 
maintaining genomic stability. However, these pathways are found to be responsible 
for therapeutic resistance to cancer therapies causing DNA damage. Platinum-
containing drugs are important therapies for various solid tumors. Genetic 
polymorphisms in NER and BER genes have been identified, and some have been 
correlated to altered clinical outcome to platinum-based chemotherapies. Here I 
studied the genetic polymorphisms in the NER genes, ERCC1 and XPD, and the BER 
genes, XRCC1 and PARP1, and found that the polymorphic variants had significantly 
higher frequencies in European Americans (EAs) for ERCC1 N118N (p<0.000001), 
XPD K751Q (p=0.006675), XRCC1 R399Q (p<0.000001) and PARP1 V762A 
(p=0.000001), compared to those in African Americans (AAs), which may reflect a 
mild reduction in DNA excision repair function in EA population. However, these 
polymorphisms were not associated with risk of prostate cancer or the clinical 
outcome of radiation therapy in prostate cancer in EAs. I also investigated the 
functional consequences of the most well studied NER polymorphism ERCC1 
N118N (500C>T) by introducing the ERCC1 cDNA clones containing either the C or 
T allele into an ERCC1 deficient cell line UV20. However, neither the ERCC1 
expression levels nor the cellular sensitivity to platinum drugs were affected by this 
silent mutation. These data suggests that the N118N itself does not contribute to the 
phenotypic differences in ERCC1, but rather this polymorphism may be linked to 
other causative variants or haplotypes. Therefore, I examined 4 polymorphisms in 
ERCC1, including rs3212948 (G>C), rs3212950 (C>G) in intron 3, and rs3212929 
(T>G) in the 5’ UTR, in addition to N118N (500C>T), and found that the haplotypes 
of these polymorphisms were associated with risk of skin melanoma, indicating the 
potential functional significance of other ERCC1 polymorphisms. Understanding the 
functional significance the genetic polymorphisms in DNA excision repair genes may 
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1. Introduction  
1.1. Platinum containing drugs  
Platinum containing drugs are currently used for treating cancer, and are 
actually the largest class of drugs used in cancer treatment. Their therapeutic use was 
discovered accidentally in the 1960s when Rosenberg and his coworkers (1) were 
studying how electric or magnetic dipole fields might be involved in cell division. 
The Escherichia coli cells in the chamber containing a set of platinum electrodes, 
which were considered to be inert, appeared as very long filaments rather than as the 
normal short rods. A chemical analysis followed and revealed that the electrolysis 
products arising from the platinum electrodes were causing the biological effect and 
the active product was subsequently named cisplatin. In 1968, cisplatin was given to 
mice bearing a standard murine transplantable tumor, and caused marked tumor 
regression (2). Since then, platinum-based drugs have been widely used against 
various solid tumors. Over the years cisplatin has significantly improved the disease 
free survival in patients with testicular cancer when discovered early, hence becoming 
an essential component of the chemotherapy regimen. The major platinum containing 
drugs are cisplatin, carboplatin, oxaliplatin and satraplatin. They destroy cancerous 
cells primarily by interfering with and causing cross-links in DNA, thereby triggering 
apoptosis.  
Cisplatin was approved by the Food and Drug Administration (FDA) for the 
treatment of metastatic testicular and ovarian cancers in 1978 and transitional bladder 
cancer in 1993 (3). Though important in cancer treatment, cisplatin has some 
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drawbacks such as severe cytotoxicity, drug resistance and poor oral bioavailability. 
Cisplatin has cis-diammine as its carrier ligand and chloride as its leaving group. 
Carboplatin, approved in 1989 for ovarian cancer, shares the same carrier ligand with 
cisplatin but has a bidentate dicarboxylate ligand as its leaving group (refer to Figure 
1-1). It is less toxic than cisplatin and can thus be given at a much higher dose than 
cisplatin, although it is only active in the same range of tumors as cisplatin (4). 
Oxaliplatin, approved for colorectal cancer in 2002, has a 1,2-diaminocyclohexane 
(DACH) carrier ligand, and has shown efficacy in cisplatin- and carboplatin-resistant 
tumor cell lines, indicating the important role that carrier ligands play in the 
specificity of tumor cytotoxicity. Satraplatin is the first orally available platinum-
containing drug and has been under consideration for approval by the FDA for 
hormone-refractory prostate cancer (HRPC). It has two chlorine atoms attached to the 
platinum as in cisplatin, but differs from it with two acetate groups attached, and a 
cyclohexyl moiety substituted on one of the amino groups. Satraplatin shows similar 
anti-tumor activity to that of cisplatin and carboplatin but has an improved 
cytotoxicity profile and less cross-resistance to cisplatin (5). Nedaplatin is a second-
generation platinum analog and is closely related to cisplatin in its chemical structure. 
It contains a ring structure in which glycolate is attached to the platinum by a 
bidentate ligand and has shown reduced cytotoxicity (6). It has been exclusively used 
in Japan to treat several types of cancers, such as head and neck, ovarian and lung 
cancer (3). Picoplatin is rationally designed to provide a bulkier carrier ligand and has 
subsequently shown less cross-resistance with cisplatin and carboplatin in vitro (7). It 
has shown clinical efficacy in cisplatin resistant small cell lung cancer (8). Figure 1-1 
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shows the chemical structures of the major platinum-containing drugs mentioned 
above.  
One major challenge in applying and designing the platinum compounds has 
been overcoming the intrinsic resistance, mostly seen in colorectal cancer, prostate 
cancer, lung and breast cancer, or the resistance that is acquired during treatment 
cycles, as seen in ovarian cancer.  
 
Figure 1-1: Chemical structures of major platinum compounds: cisplatin (1), 
carboplatin (2), nedaplatin (3), oxaliplatin (4), satraplatin (5) and picoplatin (6). 
1.2. Mechanisms of action  
1.2.1. Drug accumulation 
Cisplatin is the first member of the class of platinum containing anti-cancer 
drugs and provides the structural basis for the rational design of other platinum 
analogs. It has two chloride ion ligands situated adjacent to one another and two 
relatively inert ammonia ligands in a square planar structure. Once the drug is in the 
bloodstream, it remains intact due to high concentrations of chloride ions (~100mM). 
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Cisplatin primarily enters cells by passive diffusion (9), but specialized transporters 
such as copper transporters (CTR1) and copper-transporting P-type ATPases (ATP7A 
and ATP7B) can also facilitate its uptake and efflux (10). Once cisplatin has entered 
the cells, aquation and reactions with the cellular components take place. Specifically, 
inside the cell, the two chloride ions are substituted with water due to the relatively 
low intracellular concentrations of chloride ions (~3-20 mM), whereas the two 
ammonia ligands remain intact and are known to carry anti-tumor activity. The 
aquated species then goes on to react with nucleophilic groups such as DNA, RNA, 
proteins, membrane phospholipids, and microfilaments (11).  
1.2.2. Binding to DNA 
Cisplatin primarily causes cytotoxicity by binding to the DNA and producing 
DNA-distorting lesions. The first clues of DNA being the primary target for cisplatin 
were the filamentous growth of the bacteria induced by cisplatin (1) and lysis of 
Escherichia coli cells containing bacteriophage λ (12), characteristics shared by DNA 
damaging agents. Cisplatin binds preferentially to the N7 positions of two adjacent 
guanines or a guanine and an adenine located in the major grooves of the double helix 
(13). The major platinum-DNA adducts are 1,2-d(GpG), 1,2-d(ApG) and 1,3-
d(GpXpG) intrastrand cross-links, which account for 60−65% of adducts formed by 
cisplatin (Figure 1-2). A small portion of interstrand cross-links and monofunctional 
adducts are also present (14). There is still debate on which types of cisplatin-DNA 
adducts are the most important in mediating cytotoxicity of the drug. Since 
transplatin, the inactive trans isomer of cisplatin, mainly forms 1,3-intrastrand and 
interstrand cross-links, it is believed that the 1,2-intrastrand adducts formed by 
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cisplatin play the most significant role in inducing tumor cell death (15, 16). 
Moreover, it has also been found that the 1,2-intrastrand adducts are more resistant to 
DNA repair by human cell extracts (17). However, the cytotoxic effects caused by the 
minor types of DNA cross-links should not be overlooked. For example, the 
interstrand cross-links formed by cisplatin can cause the extrusions of cytosines of the 
cross-linked sites, the bending of the helix towards the minor groove, and a large 
DNA bending, although the interstrand cross-links are unstable under physiological 
conditions and are easily cleaved and rearranged into intrastrand cross-links (18).  
  
Figure 1-2: Platinum-DNA adducts (19). 
1.2.3. Binding to non-DNA targets 
In addition to platinum-DNA adducts, cisplatin also binds to non-DNA 
cellular components containing the nucleophilic groups, though the contribution of 
these targets to the cytotoxic effects induced by cisplatin has been poorly studied. 
DNA-protein cross-links are also formed by cisplatin and other platinum compounds 
(20). Less than 10% of covalently bound cisplatin is found in the DNA fraction. The 
vast majority of the drug binds to proteins (21). Cisplatin binds to phosphatidylserine 
in model membranes in a pH and chloride concentration dependent manner; this 
binding is suggested to be of biological importance in the cellular processes in which 
phosphatidylserine are involved (22). Due to cisplatin’s strong reactivity against S-
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donor molecules, the most important non-DNA cellular targets of cisplatin may be 
glutathione (GSH), which presents at high cellular concentrations (0.5−10 mM). The 
binding of cisplatin and GSH is proposed to serve as a drug reservoir modulating the 
kinetics of DNA platination. On the other hand, the binding of cisplatin to sulfur 
atoms of cysteine and/or methionine residues and to nitrogen atoms of histidine 
residues in proteins may affect their functions and thus cause cytotoxicity (23). A 
study showed that cisplatin binds to ubiquitin in vitro and forms at least three 
different adducts, while transplatin only forms one major adduct and does not bind as 
efficiently as cisplatin does, suggesting that the cytotoxic effects are caused by the 
binding of cisplatin to cellular proteins (24).  
1.3. Repair of platinum-DNA adducts 
The cytotoxic effect of platinum-containing drugs is a complex process and 
involves the initial stages of the drug entry into cells, interaction with cellular 
components, and the final stages of cell death. Reduced uptake and increased efflux 
may result in lower intracellular concentrations of the drug. Increased concentrations 
of thiol-containing molecules upon chronic platinum exposure can lead to decreased 
levels of platinum available for interaction with the target DNA. The formation of 
DNA adducts is an essential step for inducing the anticancer activity by these 
compounds. Platinum-DNA adducts interrupt major cellular processes such as DNA 
replication, transcription, cell cycle checkpoint arrest and apoptosis, and are 
recognized and processed by several DNA repair mechanisms. In addition, down 
regulation of the apoptotic signal by various mechanisms or increased DNA damage 
tolerance are also considered to contribute to platinum resistance (25).  
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However, the most important mechanism by which platinum resistance occurs 
is the increased DNA damage removal by various DNA repair pathways. The 
inhibition of DNA synthesis, especially in the actively transcribed strand, by 
platinum-DNA adducts is thought to be the main contributor to the cytotoxicity of 
platinum compounds (26). Following the formation of platinum-DNA adducts, the 
cellular repair systems respond to recognize the lesion and continually act until the 
fate of the cell is decided. Multiple pathways and proteins are involved in this 
process. 
1.3.1. Mismatch repair (MMR) pathway 
MMR facilitates the repair of post-DNA replication base pairing errors and 
functions in an ATP-dependent manner. Recognition of these errors and recruitment 
of repair machinery is carried out by the MutSα complex (composed of the MMR 
proteins MSH2 and MSH6) or MutSβ complex (containing MSH2 and MSH3) (27). 
MMR proteins have been indicated to bind to cisplatin-DNA adducts and initiate 
MMR protein-dependent cell death, specifically, by caspase-dependent apoptotic 
signaling pathways. Deficient MMR function increases replicative bypass of 
cisplatin-DNA adducts and compromises cisplatin induced cell death but not 
oxaliplatin-DNA adducts (28).  
1.3.2. High-mobility-group box (HMGB) proteins 
The HMGB proteins, such as HMGB1 and HMGB2, are highly conserved, 
non-histone architectural chromosomal proteins. They have been shown to have high 
binding affinity to the intrastrand cross-links caused by cisplatin (29) but play less 
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important roles in recognizing carboplatin- and oxaliplatin-DNA adducts (30-32). 
When the HMGB proteins bind to platinum induced DNA cross-links, they are 
deprived from their natural binding sites on the genome and protect the platinum-
DNA lesions from cellular repair machineries, a process termed repair shielding. 
Over-expression of HMGB proteins has been shown to sensitize cancer cells to 
platinum containing drugs (33), possibly by reducing the recognition and removal of 
platinum-DNA adducts by other mechanisms.  
1.3.3. DNA-activated protein kinase (DNA-PK) 
DNA-PK is a nuclear serine/threonine protein kinase that requires DNA for 
activity. It mainly recognizes DNA double-strand breaks (DSB) (34) induced by 
ionizing radiation or small gaps and nicks in DNA (35). Ku is the DNA binding 
subunit of DNA-PK. It has been reported to also bind to the cisplatin-DNA adducts, 
however, the binding does not activate DNA-PK catalytic subunit (36). Nevertheless, 
Cisplatin-DNA adducts can inhibit translocation of Ku subunit along DNA, resulting 
in decreased association of DNA-PK to the Ku−DNA complex and therefore 
compromised protein kinase activity (37). 
1.3.4. Nucleotide Excision Repair (NER) pathway 
The NER pathway is the primary mechanism for removing platinum-DNA 
adducts. It has been found to excise cisplatin, oxaliplatin and satraplatin adducts with 
equal efficiency, indicating that it does not contribute to the carrier ligand specificity 
of platinum resistance (28). The molecular mechanism by which the platinum-DNA 
adducts are removed by NER has been well studied. 
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NER is a multi-step process that requires the coordination of multiple 
proteins. Based on the substrate specificity, the NER pathway can be divided into two 
sub-pathways: global genome NER (GG-NER) and transcription-coupled repair (TC-
NER), as illustrated in Figure 1-3 (38). GG-NER surveys the entire genome for 
helix-distorting injuries, while TC-NER focuses on the damage that is in the actively 
transcribed strand of a gene. The TC-NER is believed to be more important in 
repairing platinum-DNA adducts as TC-NER deficient cells are hypersensitive to 
cisplatin irrespective to their GG-NER status (39).  
1.3.4.1.Lesion detection  
The XPC-HR23B complex is the earliest damage detector to initiate GG-NER 
specifically (40). In comparison, in the TC-NER sub-pathway, RNA polymerase II 
(Pol II), and probably CSA and CSB, take the role of XPC. Elongating RNA Pol II is 
blocked by many lesions in the actively transcribed strand. The transcription bubble 
presented at the lesion can serve as an efficient damage sensor (41, 42). Once lesions 
have been detected, an open DNA complex is formed by a reaction intermediate 
composed of XPA, RPA, XPC-hHR23B plus TFIIH (Transcription factor II H). In 
this step, the DNA is unwound on either side of the lesion symmetrically and an open 
complex containing no more than 20 nucleotides is formed around the lesion. The 
addition of XPA, RPA, as well as XPG, is needed to obtain the full opening that is 
required for the following dual-incision step. XPA plays a key role in recognition of 
DNA damage and has a preference for binding to the single-stranded damaged DNA 
(43, 44). RPA binds to the undamaged DNA strand (45) and fully opens the repair 
intermediate to about 30 nucleotides in length. Independent of its 3’ incision activity, 
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XPG has a structural function in the stabilization of the open complex and the 
assembly of the NER DNA-protein complex (46).  
1.3.4.2.Dual incision 
Upon lesion demarcation, the actual incisions are carried out by the structure-
specific endonucleases ERCC1-XPF (47, 48) and XPG (49). Though in principle, 
ERCC1-XPF and XPG can cut either strand of DNA, the nucleases are directed to the 
damaged strand only during repair. The binding polarity of RPA is crucial for the 
proper positioning of ERCC1-XPF (45). XPA’s interaction with both RPA and 
ERCC1-XPF may facilitate and stabilize their binding to the DNA (50-54). RPA is 
not necessary but contributes to the proper positioning of XPG. TFIIH associates with 
XPG at physiological ionic strengths (55). The two proteins form a stable complex 
that is active in transcription and NER, suggesting that XPG and TFIIH play a role in 
stabilizing each other (56). Both TFIIH and XPG are essential for coupling 
transcription to different repair pathways, such as end joining and homologous 
recombination repair. Incisions are made asymmetrically around the lesion and the 
exact incision positions seem to depend on the type of the lesion (57). The presence, 
but not the catalytic activity, of XPG is required for the 5’ incision by ERCC1-XPF 
whereas efficient 3’ incision by XPG requires the catalytic activity of ERCC1-XPF 
(58). This indicates the importance of ERCC1-XPF in the NER pathway. The 5’ 
incision by ERCC1-XPF leaves a free 3’ hydroxyl (-OH)-group on the damaged 
strand which serves as the primer for repair synthesis. 
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1.3.4.3.Repair synthesis 
After the incision, most NER proteins leave the repair complex before repair 
synthesis. However, RPA remains bound to the undamaged strand to protect the 
template strand against nucleases, and may facilitate replication. The DNA repair 
synthesis that follows requires either DNA Pol δ or ε with their cofactors, 
proliferating cell nuclear antigen (PCNA) and replication factor C (RFC). Briefly, 
RFC preferentially binds to the 3’ end of DNA primers and facilitates the loading of 
PCNA, which forms a trimeric ring-shaped clamp that can travel along the duplex 
DNA. This complex serves as a docking platform for both Pol δ and Pol ε, which 
carry out single-stranded DNA synthesis using the undamaged strand as the template. 
An illustration of the process is shown in Figure 1-4. Finally, the NER is completed 
by the ligation of the newly synthesized patch to the original sequence, which is 





Figure 1-3: Molecular mechanisms for the Nucleotide excision repair (38). In 
global genome NER (GG–NER) (Left), the hetero-dimeric protein complex XPC–
hHR23B (represented by the letter C on the double helix) senses DNA helix-
distorting lesions, leading to conformational alterations of the DNA. In transcription-
coupled repair (TC–NER) (Right), lesions are detected by elongating RNA 
polymerase II (Pol II) blocked by DNA lesions. In GG-NER, XPC–hHR23B at lesion 
recruits TFIIH, and possibly XPG (represented by the letter G) to the distorted DNA. 
TFIIH creates a 10- to 20-nucleotide opened DNA complex around the lesion by 
virtue of its helicase subunits XPB and XPD; this step requires ATP. XPC–hHR23B 
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hetero-dimer may be released at this or one of the subsequent steps. In TC-NER, 
CSA, CSB, TFIIH, XPG, and possibly other cofactors displace the stalled Pol II from 
the lesion, which now becomes accessible for further repair processing; depending on 
the type of lesion, repair is completed by NER or by other repair pathways. The 
single strand-binding proteins XPA (represented by the letter A in the complex) and 
RPA stabilize the opening caused by TFIIH and recruit and position other proteins. 
XPG stabilizes the fully opened complex. XPG, positioned by TFIIH and RPA, 
makes the 3′ incision. ERCC1–XPF (represented by the letter F in the complex), 
positioned by RPA and XPA, makes the second incision 5′ of the lesion. This is the 
critical step of the NER process. Dual incision is followed by gap-filling DNA 








Modified from http://asajj.roswellpark.org/huberman/dna_repair/ner.html 
Figure 1-4: Repair synthesis after the dual incision in NER. Before repair synthesis, 
most proteins in the repair complex have left except RPA, which remains bound to 
the undamaged DNA strand as a protection from its being attacked by nucleases and 
facilitation of following DNA replication. Then RFC is recruited to bind to the 3′ 
termini of DNA primers and facilitate the loading of PCNA. The complex formed by 
RFC and PCNA serves as a docking platform for both Pol δ and Pol ε, which 
accomplishes the synthesis of the single-stranded DNA using the undamaged strand 
as the template. DNA ligase I fixes the nick between the newly synthesized patch and 
the original sequence. 
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Reduced expression of NER proteins, such as XPA, ERCC1 and XPF, is 
found in testis tumor cell lines (59, 60) and is suggested to be responsible for the 
exceptional sensitivity of testicular tumors to cisplatin. Greater levels of ERCC1 and 
XPC mRNA are found in tissues from patients with ovarian cancer that are clinically 
proven to be resistant to platinum-based chemotherapy (61). The suppression of the 
XPF-ERCC1 complex significantly decreases cellular viability which correlates with 
the decrease in DNA repair capacity (62). In vitro repair assays have shown that 
inhibition of NER results in failure to remove a site-specific d(GpG) cisplatin adduct 
by strongly inhibiting DNA repair synthesis and less strongly inhibiting incision and 
ligation (63). Common genetic polymorphisms in NER genes have been discovered 
and their associations with the clinical outcome of platinum-based chemotherapies 
have been widely investigated and reported, as discussed in following sections. 
1.3.5. Base excision repair (BER) pathway 
In addition to the NER pathway, other DNA repair mechanisms have been 
found to contribute in removing platinum-DNA adducts, depending upon the type of 
damage it causes. The BER pathway protects cells from endogenous DNA damage 
and lesions caused by ionizing radiation and strong alkylating agents. It is important 
in cancer and chemotherapies that cause DNA damage, such as platinum-containing 
drugs and radiation, which will be discussed in detail in chapter 3.  
BER begins with an abasic site that is generated by glycosylases or by 
spontaneous hydrolysis. The core BER reaction is initiated by strand incision at the 
abasic site by the APE1 endonuclease (64). Poly(ADP-ribose) polymerase 1 (PARP1) 
binds to and is activated by DNA strand breaks (65). If BER is initiated from a single 
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strand break, the polynucleotide kinase (PNK) is important to protect and trim the 
ends for repair synthesis (66). This is followed by the one-nucleotide gap-filling by 
DNA Pol ß and the removal of the 5'-terminal baseless sugar residue via its lyase 
activity (67). The remaining nick is sealed by the XRCC1-ligase 3 complex (68). The 
XRCC1 scaffold protein interacts with most of the above BER core components and 
may therefore be instrumental in protein exchange. This is the so-called short-patch 
repair and is the dominant mode in mammals. The long-patch repair mode requires 
DNA Pol ß, Pol δ/ε and PCNA to synthesize the 2–10 bases of nucleotides using the 
other strand as the template, as well as the FEN1 endonuclease to remove the 
displaced DNA flap, and DNA ligase 1 to seal the end (69). In some cases, the BER 
lesions block transcription. The problem is resolved by coupling with the TC-NER 
pathway described above. Thus, the BER pathway is joined with the NER pathway. 
An illustration of the BER pathway is shown in Figure 1-5.  
BER is suggested to have an additional role in processing DNA damage 
caused by anti-tumor agents, and may share the similar mechanism of the MMR 
pathway in responding to DNA damage (70). Though little evidence suggests that the 
BER pathway plays direct roles in repairing platinum-caused DNA damage, the 
genetic polymorphisms in several BER genes have been found to be associated with 
clinical outcomes of platinum-based chemotherapies, which will be discussed in more 
details in later sections in this chapter.   
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Figure 1-5: The molecular mechanism of the BER pathway (71). 
1.4. Pharmacogenetics in DNA excision repair genes 
Unpredictable efficacy and toxicity are major hurdles in drug development, 
especially in cancer treatment as most of the chemotherapy agents are extremely 
toxic. Many drugs that show therapeutic potential never get approved because of their 
adverse effect in some individuals, while others show effectiveness only in some of 
the patients that have received the treatment. Thus pharmacogenetics is an important 
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research field with both biomedical and commercial significance by identifying 
inherited DNA polymorphisms that could influence drug disposition and effects. 
Single nucleotide polymorphisms (SNPs) are DNA sequence variations that 
occur when a single nucleotide (A, T, C or G) in the genomic sequence is altered. 
SNPs make up about 90% of all human genetic variation and occur every 100 to 300 
bases along the 3-billion-base human genome. Many SNPs have no effect on cellular 
function, but some predispose people to disease or influence their response to a drug. 
Common SNPs are found in most DNA excision repair genes. There is cumulative 
evidence that altered DNA repair capacity, implied by the common variations in 
DNA repair genes, might affect cancer disposition and response to DNA damaging 
chemotherapy regimens. 
1.4.1. ERCC1 
ERCC1 was the first gene cloned in the NER pathway (72). It is located on 
chromosome 19q13.2-q13.3 with 10 exons spread over 15-kb on the chromosome, 
and encodes a protein approximately 33 kDa in size. The gene product of ERCC1 
forms a tight complex with XPF, its catalytic partner. The formation of the hetero-
dimeric protein complex is important for both the stability of the two proteins in vivo 
and in vitro, and their proper functionality in DNA lesion incisions. The structure-
specific dimeric endonuclease ERCC1-XPF cleaves strands containing DNA 
distorting lesions from the 5’-end. During NER, this activity is required to create a 
nick 5’ to the lesion, releasing a 3’ single-stranded DNA for further repair synthesis. 
However, the function in DNA repair of the ERCC1-XPF hetero-dimer is not limited 
to NER only. The ERCC1-XPF complex also plays an important role in homologous 
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recombination repair by removing long non-homologous tails from invading 
homologous strands (73), and is critical in removing interstrand cross-links (ICL) 
(74). 
Though the inter-individual variations in response to platinum-based 
chemotherapy are widely observed, the genetic basis is not fully understood. A large 
body of evidence suggests that ERCC1 mRNA and/or protein expression levels may 
correlate with platinum resistance. Suppression of ERCC1 either enhances platinum 
sensitivity in human cancer cells or restores the platinum sensitivity in resistant cells 
(75-80). Greater levels of ERCC1 mRNA are found in ovarian cancer tissues resistant 
to platinum-based chemotherapy (61). In patients with non-small-cell lung cancer 
(NSCLC), ERCC1-negative tumors are found to benefit from cisplatin-base adjuvant 
chemotherapy (81-83). Patients with advanced head and neck squamous cell 
carcinoma that are characterized by low ERCC1 expression have a 4-fold greater 
odds of benefiting from an objective response to chemotherapy compared with 
patients with high ERCC1 expression (84). The ERCC1 promoter is located in a 
region of ±170 bps upstream of the transcriptional start site of this gene (76). A 
computer analysis of the transcriptional factors binding sites in the 5’-flanking region 
of ERCC1 (−415 to +32 bp) revealed 7 transcription activators and 1 transcription 
repressor binding sequences (85). However, the regulation of ERCC1 expression is 
less studied with only AP1 (86) and MZF1 (85) having been investigated.  
The ERCC1 N118N (500C>T) polymorphism was first reported by Reed and 
colleagues (87). It has been the focus of many genetic association studies, and has 
shown the potential as a predictive marker in patients treated with platinum-based 
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chemotherapy in several cancers, as summarized in Table 1-1. However, the results 
vary in different types of malignancies. For example, in NSCLC, some studies 
suggest that the C allele signifies a better response to platinum-based chemotherapy 
(88-91), while others reported no association (92, 93). Alternatively, in metastatic 
colorectal cancer, both C and T alleles were found to be associated with either an 
improved or impaired outcome.  
 
Table 1-1: Previous pharmacogenetics studies on ERCC1 N118N polymorphism in 
multiple malignancies. mCRC: metastatic colorectal cancer, NPC: Nasopharyngeal 
Carcinoma, EOC: Epithelial Ovarian Cancer, NSCLC: Non-Small Cell Lung Cancer, 
PFS: Progression free Survival, OS: Overall Survival, HR: Hazard Ratio. 
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Disease Therapy # of pts Association HR (95% CI) P value Ref. 
FOLFOX 118 T allele: worse progression-free survival 
2.62 (1.14-
6.0) 0.02 (94) 
FOLFOX 168 
T allele: increased ERCC1 
expression, lower response, 
and shorter OS and PFS 
N/A ≤ 0.01 (95) 
Fluorouracil/oxaliplatin 49 C allele correlated with a shorter PFS 
1.96 (0.99–
3.92) 0.050 (96) 
Platinum-based 
chemotherapy 106 
CC genotype had longer 
median survival N/A N/A (97) 
Oxaliplatin/5-
fluorouracil  91 
TT genotype had higher 




CC genotype showed the most 
favorable survival 
2.29 (1.19, 






carboplatin 153 No association 
1.2 (0.74-
1.96) 0.45 (92) 
Platinum-based 
chemotherapy 119 
C allele associated with better 
response 
0.10 (0.013-
0.828) 0.033 (88) 
Cisplatin combination 245 CC had longer OS in patients having over 50 packs per year N/A 0.03 (89) 
Docetaxel-cisplatin 62 CC genotype had longer OS  0.01 (90) 
Platinum-based 









chemotherapy 67 T allele: longer PFS and OS  
0.006 for PFS 
and 0.03 for OS (100) 
 EOC Platinum-based chemotherapy 159 
TT signalized a better 




adjuvant chemotherapy 102 No association N/A > 0.05 (102) 
Esophageal 
cancer Cisplatin 
262 with or 
108 without 
cisplatin 
No association N/A 
0.1 for cisplatin-
treated and 0.49 
for no-cisplatin 
(103) 




Another SNP in ERCC1, C8092A, is found in the 3'-UTR of the gene. It has 
been suggested to be an indicator of altered chemo-sensitivity. The homozygous wild 
type CC is found to be associated with shorter median survival time compared to CA 
and AA genotypes in patients with advanced NSCLC who received platinum-based 
chemotherapy (88). However, other studies found that individuals with the CC 
genotype benefit from platinum-based chemotherapy (93, 105) or no association 
(106).  
1.4.2. XPD 
XPD (also called ERCC2), one of the two subunits of TFIIH, is a 5’-3’ 
helicase that participates in DNA strand separation prior to the 5’ incision step 
performed by the ERCC1-XPF heterodimer (107, 108). Although several 
polymorphisms have been reported in this gene, the most frequent is the K751Q 
(A>C) polymorphism. The interethnic variance of XPD polymorphisms has been 
previously reported among European, African and Asian populations (109). The 
lowest variant allele frequency occurs in Asians and the highest in Europeans, with 
Africans having a median variance rate. The homozygous wild type (AA) is 
correlated to suboptimal DNA repair of X-ray-induced DNA damage (110). Also, the 
AA genotype is found to be beneficial in patients with colorectal cancer treated with 
oxaliplatin-based chemotherapy (111, 112), patients with advanced NSCLC treated 
with platinum-based chemotherapy (113), and patients with acute myeloid leukemia 
treated with radiotherapy and chemotherapy (114). However, the CC variant is 
associated with reduced DNA repair capacity in patients with lung cancer (115) and is 




considered to be clinically useful molecular predictors for overall NER activity, and 
have been studied in bladder, lung, ovarian, colorectal, and other cancers where 
platinum compounds are used (97, 110, 111, 113, 117-122).  
1.4.3. XRCC1 
XRCC1 was the first human gene cloned in the BER pathway; it encodes a 
633 amino acid protein. XRCC1 works as a stimulator and scaffold protein for other 
enzymes involved in the BER pathway. It interacts with DNA ligase-III, DNA Pol β 
and poly(ADPribose) polymerase (PARP1), and assists in sealing the nick in DNA 
after DNA Pol β has filled the nucleotide gap. Cells lacking this gene product are 
hypersensitive to ionizing radiation. Approximately half of the more than 60 validated 
polymorphisms in XRCC1 are located in exons or promoter regions (123). The most 
extensively studied SNPs are R399Q in exon 10 and R194W in exon 6. The R399Q 
polymorphism is in the BRCT1 domain, which provides a binding site for PARP1 
polymerase (124). The wild type GG appears to be associated with increased 
sensitivity to platinum-based chemotherapy in cervical cancer in Asian populations 
(125) and in one study of 112 patients with non-small cell lung cancer (126), while 
the variant allele showed improved survival in one Spanish population (127) and in 
bladder cancer (122). The variant AA genotype is associated with smoke-induced 
pancreatic cancer (128), and is associated with breast cancer risk in African 
Americans (129).  
Another prevalent polymorphism in XRCC1 is at codon 194, which is in a 
possible binding site for several protein partners in BER, and the positively charged 




and DNA repair efficiency (130), and the variant allele was associated with a better 
response to platinum-based chemotherapy in patients with advanced NSCLC (131).  
1.4.4. PARP1 
Poly(ADP-ribose) polymerase 1 (PARP1) is a DNA repair enzyme that 
catalyzes the poly(ADP-ribosyl)ation of proteins using NAD+ as the substrate. 
PARP1 is activated 100-fold by DNA damage and has a major role in the BER 
pathway (132, 133). A common PARP1 polymorphism at codon 762 results in the 
substitution of valine by alanine in the catalytic domain. This change was proven to 
dramatically reduce the enzymatic activity (134). The variant genotype contributes to 
prostate cancer susceptibility and altered DNA repair function to oxidative damage 
(135), association with risk of esophageal squamous cell carcinoma in a Chinese 
population (136) and increased risk of smoking-related lung cancer (137).  
1.5. DNA repair and cancer 
Genomic stability is important for preventing oncogenesis. All cancers are 
thought to be caused by gene mutations. The lesions in DNA can arise from 
endogenous and environmental causes. The endogenous damage includes mismatches 
that arise during DNA replication, (by)products of normal cellular processes, such as 
reactive oxidative species (ROS) derived from oxidative respiration and products 
from lipid oxidation, and spontaneous nucleotide hydrolysis which creates abasic 
sites. Spontaneous or induced deamination of cytosine, adenine, guanine or 5-
methylcytosine converts these bases to the miscoding uracil, hypoxanthine, xanthine 




ultraviolet (UV) component of sunlight that produces cyclobutane pyrimidine dimers 
and other photoproducts, ionizing radiation that generates base damage and strand 
breaks, alkylating agents that alkylate bases, cross-linking agents that create 
intrastrand and/or interstrand covalent links and double-stranded DNA breaks, and 
other genotoxic chemicals such as cigarette smoke.  
The outcome of DNA damage is generally adverse. All eukaryotic cells have 
evolved multifaceted mechanisms to counteract the potential deleterious effects of 
DNA damage.  Acute effects trigger cell cycle checkpoint arrest to allow time for 
repair or cell death. Chronic effects arise from irreversible or unrepaired mutations 
that lead to oncogenesis. With the various types of DNA damage, no single repair 
pathway can cope with all kinds of damage. Instead, human cells have evolved 
sophisticated, interwoven DNA repair systems, including MMR, BER, 
recombinational repair (Homologous Recombination and End Joining), and NER. If, 
despite these repair mechanisms, DNA damage persists, cells can make use of a 
mechanism called translesion synthesis, which uses special DNA polymerases to 
bypass these specific types of DNA lesions.  
In general, multiple mutations are needed to transform a normal cell into a 
tumor cell. However, normal human cells replicate their DNA with exceptional 
accuracy. The average frequency of spontaneous mutations in normal tissues is less 
than 1 x 10-8 per base pair, whereas the frequency of mutations increases at least two 
orders of magnitude in tumors from the same individuals (139). Therefore, tumor 
cells must exhibit a “mutator” phenotype arising from inherited or acquired faulty 




mechanisms can lead to more than 1000-fold increased in cancer risk (141), thus 
underscoring the importance of DNA repair mechanisms in carcinogenesis.  
1.6. Summary and research goal 
DNA repair is a double-edged sword. It guards our genome, protecting us 
from endogenous and exogenous DNA damage, while causes resistance to cancer 
therapies that take effects by causing DNA damage. Although many studies have 
investigated the genetic polymorphisms in DNA excision genes in the context of 
cancer risk and clinical outcome of platinum-based chemotherapy and radiation 
therapies, there is still a lack in our understanding of the biological consequences of 
these genetic polymorphisms and how they can contribute to improved delivery of 
cancer therapies. We are particularly interested in how the genetic polymorphisms in 
DNA excision genes are associated with inter-individual and inter-populational 
differences in cancer incidence, how they may affect the respective gene expression 
and biological function, and what the functionally important polymorphisms are in 
genes involved in the DNA excision repair pathways. The aim of this dissertation 
research is to increase our understanding in these areas, and we focused our study on 










2. Ethnic disparity in DNA excision repair gene 
polymorphisms 
2.1. Abstract  
NER and BER pathways are DNA repair pathways that are important in 
carcinogenesis and in response to DNA damaging chemotherapy. ERCC1 and XPD 
are important molecular markers for NER; XRCC1 and PARP1 are important 
molecular markers for BER. Functional polymorphisms have been described that are 
associated with altered expression levels of these genes, and with altered DNA repair 
capability. We assayed genomic DNA from 156 Americans of European descent 
(EAs) and 164 Americans of African descent (AAs), for the allelic frequencies of 
specific polymorphisms of ERCC1 N118N (500C>T), ERCC1 C8092A, XPD K751Q 
(2282A>C), XRCC1 R399Q (1301G>A), XRCC1 R194W (685C>T) and PARP1 
V762A (2446T>C).  Differences were observed between EAs and AAs in the allelic 
frequencies of the ERCC1 N118N polymorphism (p<0.000001), XPD K751Q 
(p=0.006675), XRCC1 R399Q (p<0.000001) and PARP1 V762A (p=0.000001). The 
polymorphic variants of DNA excision repair genes that are seen most commonly in 
EAs may reflect a mild reduction in NER and BER function, thus the repair of 
cisplatin-DNA lesions.  
2.2. Introduction  
Nucleotide excision repair (NER) is the DNA repair pathway that repairs 




from ultraviolet light, polycyclic aromatic hydrocarbons, and selected anticancer 
pharmaceuticals such as the platinum compounds, e.g., cisplatin, carboplatin, and 
oxaliplatin (142, 143). ERCC1 and XPD are two of the multiple proteins that 
participate in NER to excise the bulky lesion from the DNA strand (144, 145). 
ERCC1 performs a number of functions, and, along with XPF, is essential for the 5’ 
incision into the DNA strand that releases bulky DNA lesions (146, 147).  XPD is a 
5’-3’ helicase that participates in DNA strand separation, prior to the 5’ incision step 
performed by the ERCC1-XPF heterodimer (107, 108). The functions of ERCC1 and 
XPD are discussed in chapter 1. They are important clinical predictors for NER 
activity and have been extensively studied in many types of cancer, especially those 
where platinum-containing drugs are widely used.   
Spontaneous DNA hydrolysis, oxidative damage to DNA, as well as simple 
alkylations to DNA bases are repaired by the BER pathway. BER has not been as 
well studied as NER in the setting of anti-cancer chemotherapy. However, data 
suggests that BER may play a role in clinical and cellular resistance to simple 
alkylating agents (148). The important enzymes involved in BER include XRCC1 and 
PARP1. XRCC1 stimulates endonuclease activities following the excision of a 
damaged nucleotide, and acts as both a scaffold and a regulator for other BER 
proteins (130). PARP1 is a zinc-finger DNA-binding enzyme that is activated by 
DNA breaks and converts DNA damage into intra-cellular signals that either trigger 
DNA repair by the BER pathway or cell death. PARP1 is required for XRCC1 




sensitizing chemotherapy and radiation therapy that damage DNA. Thus, PARP1 
inhibitors are being actively investigated to facilitate cancer therapy. 
There are several common diseases where there is a long history of ethnic 
differences in treatment outcomes and mortality. These include breast cancer, prostate 
cancer, lung cancer, and colorectal cancer as summarized in Table 2-1. Breast cancer 
is treated with adriamycin and cyclophosphamide, drugs which cause oxidative 
damage to DNA (150) and alkylation of DNA, respectively (151). In these 
circumstances, BER may be of major importance. Lung cancer is commonly treated 
with cisplatin or carboplatin based regimens (152), while colorectal cancer is 
commonly treated with an oxaliplatin-based combination (153). In lung cancer and 
colorectal cancer, NER appears to be the most important DNA repair mechanism 
(142). Bladder cancer, cervical cancer, stomach cancer, and head and neck 
malignancies are also treated with DNA damaging therapies and have had ethnic 
differences in disease outcome observed (154). 
Ethnic disparity in treatment outcomes is a problem that is receiving increased 
recognition in clinical oncology, but has been poorly studied. It is not completely 
clear whether differences noted between EAs and AAs in treatment outcomes are due 
to matters of patient access to care, differences in medical care delivery, differences 
in clinical response to the same therapies, or most likely, a combination of all of 
these.  The molecular causes of clinical resistance to chemotherapy have been 
elucidated for some of the commonly used anticancer agents. For example with 
cisplatin, carboplatin, and oxaliplatin, the NER DNA repair pathway appears to be of 




cells, or produce simple alkylations to DNA, are more influenced by the BER 
pathway (71, 155). This information led us to investigate the following: if ethnic 
differences exist in the clinical treatment outcomes of patients who are treated with 
drugs that may be impacted by NER and/or by BER, are these outcomes associated 
with ethnic differences in polymorphism frequency in genes that are involved in these 
DNA repair pathways? 
ERCC1, XPD, XRCC1 and PARP1, each have been reported to have 
polymorphic variants that appear to impact the functioning of the respective gene. 
Also, for ERCC1, XPD and XRCC1, the polymorphic variants have been associated 
with clinically important endpoints. The aim of this study is to assess the allelic 






Table 2-1: summary of previous studies on racial disparity of mortality and treatment outcome in cancer. 
* EA: Americans of European descent, AA: Americans of African descent, *Breast-cancer-specific survival, adjusted for tumor 
characteristics and major treatments, †Lymph node-negative disease, ‡Lymph node-positive disease, ††Adjusted only for age, 
‡‡Adjusted for stage, treatment, grade, socioeconomic status and year of diagnosis, †††Within 5 years of surgery, ‡‡‡Within 10 years of 
surgery.
Cancer type Treatment  Ethnic groups (# of 
samples) 
Major findings OR (95% CI)/P value Ref. 





2.27 (1.82,2.84) (156) 
Surgery, radiation and adjuvant 
chemotherapy 
AA (771) and EA 
(5651) 
Increased risk of death 
in AA patients 
1.57 (1.18,2.10)* (157) 
Breast cancer 
Surgery, cyclophosphamide, 
methotrexate, and 5-fluorouracil  
AA (543) and EA 
(7582) 
Increased death in AA 
patients 
1.21 (1.01,1.46) † 
1.18 (1.03,1.34) ‡ 
(158) 
Orchiectomy or LHRH analogue 
therapy 
AA (55) and EA (90) No difference  (159) Prostate 
cancer 
Surgery, radiation, hormone 
therapy and others 
AA (14,307) and EA 
(108,067) 
Increased risk of death 




Lung cancer Not defined. AA and EA, numbers 
not defined 
Lower 5-year survival 
rate in AA patients. 
P ≤0.0001 (161) 
Colorectal 
cancer 
Surgery  AA (199) and EA 
(292) 
Lower 5- and 10-year 
survival rate in AA 
1.67 (1.21,2.33) †††  
1.52 (1.12,2.07) ‡‡‡  
(154) 
Rectal cancer Methyl-lomustine, vincristine, 
fluorouracil, leucovorin and/or 
radiation therapy after surgery 
AA (104) and EA 
(1,070) 
Higher mortality in AA 
patients 
1.45 (1.09,1.93) (162) 
Colon cancer Not defined. AA (454) and EA 
(521) 
Higher risk of death 
among AA patients after 
adjusted for stage 




2.3. Materials and Methods 
2.3.1. Sample collection & DNA isolation 
320 whole blood samples, 156 EAs and 164 AAs, from healthy male 
volunteers (Valley Biomedical Inc., Winchester VA) were analyzed. All volunteers 
gave informed consent to allow their samples to be used for genotyping, and none had 
a diagnosis of cancer. Plasma was the source used to isolate genomic DNA using the 
UltraSens Virus Kit following the manufacturer’s instructions (Qiagen, Valencia, 
CA).  
2.3.2. Genotyping methods  
2.3.2.1.Polymerase Chain Reaction (PCR)  
PCR was performed using the Platinum Taq PCR Kit from Invitrogen 
(Carlsbad, CA) with gene-specific primers. PCR reactions were denatured at 94°C for 
5 min, followed by denaturation at 94°C for 30 sec; annealing at optimal temperature 
for each pair of primers for 30 sec and synthesis for 30 sec at 72°C for 40 cycles; the 
final extension was carried out at 72°C for 7 min. PCR efficiency was examined by 
electrophoresis on 2% agrose gels. 50 to 150 ng of template DNA were used for each 
PCR, depending on the quality of the DNA samples.  
2.3.2.2.SAP purification of the PCR product  
After PCR, the product was purified by adding 1 U of shrimp alkaline 
phosphatase (SAP) and 3 U of exonuclease I (Exo I) to 15 ul of PCR product and 





Direct nucleotide sequencing PCR was conducted using the Big Dye 
Terminator Cycle Sequencing Ready Reaction kit V3.1 (Applied Biosystems, Foster 
City, CA). The sequencing reaction was carried out by mixing 3 ul from the SAP and 
Exo I treated PCR product above to 1ul of BigDyeTM terminator mix, 1.6 pmole of 
sequencing primer, and sterile H2O to bring the final volume to 15 ul. The PCR 
reaction was denatured at 94°C for 5 min, followed by denaturation at 96°C for 10 
sec; annealing at 50°C for 5 sec and amplification for 4 min at 60°C for 25 cycles; no 
final extension was needed for the sequencing PCR. Primers and PCR conditions are 
listed in Table 2-2. 
2.3.2.4.Direct sequencing 
Before loading the sequencer, the DNA samples were processed using the 
PERFORMA® DTR V3 96-Well Short Plates (Edge BioSystems, Gaithersburg, MD) 
to remove extra dye terminators, along with dNTPs, salts and other low molecular 
weight materials from the sequencing reactions. An ABI Prism 3130 Genetic 













Table 2-2: Primers and PCR conditions. 
 
2.3.3. Statistical analysis 
For each SNP, the genotyping results were categorized into wild type, 
heterozygotes and variant genotypes. Hardy-Weinberg Equilibrium (HWE) tests were 
conducted using the HelixTree software (Golden Helix, Bozeman, MT). P values 
were calculated by the Chi-square test using Number Cruncher Statistical Software 
(NCSS, Kaysville, Utah). 
SNPs Primers Size (bp) 
Annealing 
Temp (°C) 
ERCC1 FW 5’-TGG ATC AGA GGA TCA GGG AC-3’ 542 64 °C 
N118N RE 5’-TTC CTG AGA CCC AGG AGT TC-3’   
 Seq 5’-AGG GAG GAG GTG CAA GAA GAG-3’   
ERCC1 FW 5’- TCC TGC ACG AGC CCT TCT TG -3’ 497 66 °C 
C8092A RE 5’- TCA GGC AGC TCC CAC ATC CAC -3’   
 Seq 5’- TCC CAG GCC AGG CTC CTG C -3’   
ERCC2 FW 5’- CCT TCT CCT GCG ATT AAA GGC TGT -3’ 415 66 °C 
K751Q RE 5’- TCA GCC CCA TCT TAT GTT GAC AGG -3’   
 Seq 5’-ACC AGG GCC AGG CAA GAC TC-3’   
XRCC1 FW 5’-TGC ATC TCT CCC TTG GTC TCC-3’ 522 66 °C 
R399Q RE 5’-TGC ACA AAC TGC TCC TCC AGC-3’   
 Seq 5’-CAC CAG CTG TGC CTT TGC CA-3’   
XRCC1 FW 5’–AGA CAA AGA TGA GGC AGA GG-3’ 419 60 °C 
R194W RE 5’ – TCA ACC CTC AGG ACA CAA GAG-3’   
 Seq 5’-   AAT ACT GAC CTT GCG GGA CC -3’   
PARP1 FW 5’- TC CCA AAT GTC AGC ATG TAC GA -3’ 479 62 °C 
V762A RE 5’- TCC AGG AGA TCC TAA CAC ACA TGG -3’   




2.4. Results  
A summary of the six polymorphisms studied is provided in Table 2-3. The 
genotype distribution of each SNP is in Hardy-Weinberg equilibrium (p>0.05). No 
genotype frequency differences were observed between EAs and AAs for the ERCC1 
C8092A polymorphism. However, significant differences in genotype frequency were 
noted for the ERCC1 N118N polymorphism (p<0.000001). The CC genotype 
occurred more frequently in AAs (76%) as compared to EAs (21%), while the TT 
genotype is seen in only 3% of AAs and in 30% of EAs. The CT genotype is seen in 
21% and 49% of the respective groups. Reed and colleagues have shown that the TT 
genotype is associated with reduced expression of ERCC1, reduced cisplatin-DNA 
adduct repair, and increased sensitivity to cisplatin (87, 164).  
For the XPD K751Q (2282A>C) polymorphism, differences between EAs and 
AAs in the distribution of the AA, AC, and CC genotypes were noted (p=0.006675).  
The AA genotype was seen more frequently in AAs (56% versus 42%), but the other 





Table 2-3:  Genotype distribution. P value is calculated by Chi-square test based on allelic frequency.  
‡Indicates: gene name, amino acid change and position, nucleotide change and the position. # EA: Americans of European 
descent, AA: Americans of African descent. *Indicates: Count (frequency).
Gene Genotype EA# AA Allele EA AA P value 
ERCC1‡ CC 23(0.21)* 96(0.76) C 99(0.46) 219(0.86)  
N118N CT 53(0.49) 27(0.21) T 117(0.54) 35(0.14)  
(500C>T) TT 32(0.30) 4(0.03)     
 TOTAL 108 127 TOTAL 216 254 <0.000001 
ERCC1 CC 77(0.53) 74(0.52) C 213(0.73) 204(0.72)  
C8092A AC 59(0.40) 56(0.40) A 79(0.27) 78(0.28)  
 AA 10(0.07) 11(0.08)     
 TOTAL 146 141 TOTAL 292 282 0.870913 
XPD AA 49(0.42) 81(0.56) A 154(0.65) 219(0.76)  
K751Q AC 56(0.47) 57(0.40) C 82(0.35) 69(0.24)  
(2282A>C) CC 13(0.11) 6(0.04)     
 TOTAL 118 144 TOTAL 236 288 0.006675 
XRCC1 GG 49(0.46) 113(0.80) G 145(0.68) 252(0.89)  
R399Q AG 47(0.44) 26(0.19) A 67(0.32) 30(0.11)  
(1301G>A) AA 10(0.10) 2(0.01)     
 TOTAL 106 141  212 282 <0.000001 
XRCC1 CC 120(0.87) 133(0.90) C 257(0.93) 280(0.95)  
R194W CT 17(0.12) 14(0.09) T 19(0.07) 16(0.05)  
(685C>T) TT 1(0.01) 1(0.01)     
 TOTAL 138 148 TOTAL 276 296 0.460941 
PARP1 TT 80(0.67) 108(0.91) T 192(0.81) 227(0.95)  
V762A CT 32(0.27) 11(0.09) C 46(0.19) 11(0.05)  
(2446T>C) CC 7(0.06) 0(0)     




For the XRCC1 R399Q (1301G>A) polymorphism, substantial differences 
between ethnic groups were also noted (p<0.000001).  The GG genotype occurred in 
80% of AAs, but only in 46% of EAs.  The other two genotypes occurred more 
frequently in EAs: AG (44% versus 19%), and AA (10% versus 1%).  The XRCC1 
R194W (685C>T) polymorphism did not differ in genotype frequency between ethnic 
groups.   
The TT genotype of PARP1 V762A (2446T>C) occurred more frequently in 
AAs than EAs (91% versus 67%; p=0.000001), and the other genotypes occurred 
more frequently in EAs: CT (27% versus 9%), and CC (6% versus 0%).   
2.5. Discussion 
We assessed genomic DNA from 156 EA individuals, and 164 AA 
individuals, for allelic frequency of the noted polymorphisms in the genes ERCC1, 
XPD, XRCC1 and PARP1.  Our data suggest a profound difference between these 
two ethnic groups in three genes: ERCC1, XRCC1 and PARP1. 
Of the differences demonstrated between ethnic groups, one of the most 
interesting is the difference observed for the N118N polymorphism of ERCC1. The 
polymorphism of AAC to AAT at codon 118 of ERCC1 was first reported by Reed 
and colleagues. This codon change results in the same amino acid, but the C>T 
transition decreases the translation rate from mRNA to protein by 50% (87). This 
polymorphism was noted to be associated with reduced mRNA expression of ERCC1, 
reduced repair of platinum-DNA adducts, and greater sensitivity to platinum 




malignancies, such as lung cancer, ovarian cancer, colorectal cancer, and other 
malignancies (97, 110, 113, 118-122, 142, 165). Our data suggests the possibility that 
reduced NER capacity may occur more commonly in EAs that carry the variant T 
allele more frequently, and this might result in greater sensitivity to platinum 
compounds in EAs. This would be consistent with the observed improved survival 
rates in EAs compared to AAs in malignancies where platinum compounds are 
important components of therapy, including lung, colorectal, head/neck and ovarian 
cancers.  
Although several studies also suggested the C8092A mutation in the 3’-UTR 
of ERCC1 is an indicator of altered chemo-sensitivity (87) or cancer risk (166), we 
did not observe differences in genotype distribution of this polymorphism between 
EAs and AAs.  Therefore, this polymorphism may be important to risk and clinical 
outcome in a similar fashion in both populations, but is likely not associated with 
health disparities between EAs and AAs. 
XPD is a DNA helicase subunit of the transcription factor IIH (TFIIH), and 
catalyzes a local unwinding around a DNA lesion in a 5’->3’ direction. The TFIIH-
mediated opening generates junctions between duplex and single stranded DNA that 
in turn could be cleaved by a ERCC1-XPF heterodimer. XPD has a polymorphism at 
codon 751, K751Q (A>C), which is of particular interest. The codon 751 wild type of 
AA has been associated with suboptimal DNA repair (110). Also, the AA genotype 
has been seen with greater frequency in patients with colorectal cancer that respond to 
oxaliplatin based chemotherapy (111). These patients also show longer median 




repair capacity in patients with lung cancer (115), is significantly associated with risk 
and outcome in acute myeloid leukemia (114), and is overrepresented in patients with 
lung cancer of Chinese extraction (116). The mixed clinical picture for XPD makes it 
difficult to interpret the ethnic differences in allelic frequencies that we observe in 
this report. We report here that significantly low frequency of variant XPD K751Q 
was detected in AAs.   
The BER pathway is essential in protecting cells from endogenous DNA 
damage, as well as lesions caused by ionizing radiation and alkylating agents. When 
these lesions cause replication blockage, BER is joined to TC-NER for more efficient 
DNA damage repair.  A critical component of the BER is XRCC1, for which, one 
relevant polymorphism is at codon 399. This point mutation is in the BRCT1 domain, 
which is the docking site for PARP1 polymerase (130). Both the wild type GG 
genotype and the variant AA genotype are found to be associated with increased 
sensitivity to platinum based chemotherapy and cancer risk, but the results differ 
among populations and in different types of malignancies. The polymorphism of 
XRCC1 R194W (685C>T) is in a possible binding site for other proteins in the BER. 
This mutation causes the positively charged arginine to be changed to a hydrophobic 
tryptophan, and is susceptible to affect binding and DNA repair efficiency (130). The 
variant allele is beneficial to platinum-based chemotherapy in patients with advanced 
non-small cell lung cancer (131). Our data indicated significantly low frequency of 
XRCC1 R399Q, but not R194W, in AAs. Thus, the polymorphism of XRCC1 R399Q 





Poly(ADP-ribose) polymerase 1 (PARP1) plays various roles in molecular 
processes including DNA damage detection and repair. PARP1 expression and 
activity are generally higher in cancer than in adjacent normal tissue, but cancer 
predisposition is reported to be greater in individuals with the polymorphism V762A 
(T>C) in the catalytic domain that reduces PARP1 activity (135-137, 167). The 
prevalence of variant genotype is extremely low in AAs (0% in our samples), which 
may indicate better protein function of PARP1 in this population.  
Our data suggests the possibility that a comparatively modest reduction in 
base excision repair may occur more commonly in EAs. This would imply greater 
sensitivity to chemotherapy agents that alkylate DNA, such as cyclophosphamide, 
and/or to agents that generate free radicals that damage DNA, such as adriamycin. 
This would be consistent with observed differences in response to therapy in breast 
cancer in EA and AA patients.  
The field of genetic epidemiology has much to offer in elucidating the effect 
of heritable variations and its contribution to the observed inter-patient variances in 
response to the same chemotherapy regimen. The ethnic disparity in mortality 
between the EA and AA patients is often seen in malignancies where DNA damaging 
chemo- and radiation therapies are frequently administered. Considering the 
important roles that DNA excision repair plays in response to these therapy regimens, 
the ethnic disparity in the genetic profiles of the DNA excision repair genes may 
serve as the molecular basis of the different responses to these cancer therapies 
between EAs and AAs, although other factors can not be ruled out by this study. 




among ethnic groups, and the functional impact of these genetic polymorphisms on 
the respective genes, will facilitate clinical decision-making. Studies investigating the 
correlation between these genetic polymorphisms in DNA excision repair genes and 



















3. DNA repair polymorphisms and radiation therapy in 
prostate cancer  
3.1. Abstract 
Prostate cancer is the most frequent cancer among American men and is the 
second leading cause of cancer-related death in males. Radiation therapy is a 
potentially curative, important treatment option in localized prostate cancer. 
However, 8 years after radiation therapy, even in the low risk subset of patients, 
approximately 10% of patients will experience clinical disease recurrence. The 
identification of molecular markers of treatment success or failure may allow for the 
development of strategies to further improve treatment outcomes. Herein, we 
investigated the aforementioned molecular markers of DNA excision repair: ERCC1 
N118N (500C>T), XPD K751Q (2282A>C), XRCC1 R194W (685C>T), XRCC1 
R399Q (1301G>A) and PARP1 V762A (2446T>C), from 513 patients with castrate-
resistant prostate cancer (CRPC), including 284 patients who received radiotherapy, 
229 patients without radiotherapy, and 152 healthy individuals. The distribution of 
genetic polymorphisms in the patients with CRPC and in healthy controls was 
compared, and the association between the polymorphisms and overall survival was 
investigated. The polymorphisms evaluated did not show differences between the 
patient group and the healthy controls, nor did they show a trend toward an 




excision repair genes are not associated with risk of prostate cancer, nor are they 
predictive to the clinical outcome of radiotherapy for localized prostate cancer. 
3.2. Introduction 
Carcinoma of the prostate is the most frequent cancer among American males; 
it alone accounts for 28% of cancer cases in men (168). Prostate cancer is the second 
leading cause for cancer death in males, exceeded only by lung cancer. Although the 
specific molecular causes of prostate cancer still remain unknown, multiple etiologic 
factors, including African American ancestry, family history, increased age, genetic 
profile and environmental exposures, etc., are thought to be the risk factors for 
prostate cancer. Variations in exposure to these risk factors may account for inter-
individual differences in risk of prostate cancer. Dietary habit may also be a 
modulator of prostate cancer risk, including phytoestrogen consumption (169), meat 
consumption, vitamins E and D, dairy and calcium (170), etc., although this has not 
been demonstrated consistently in clinical studies. Hormone levels, including higher 
serum levels of testosterone and lower levels of estrogen, may influence prostate 
carcinogenesis. Therefore, it is suggested that genetic variation in androgen 
biosynthesis and metabolism may play a role in prostate cancer risk (171).  
3.2.1. DNA excision repair and prostate cancer  
DNA repair mechanisms are paramount in maintaining genomic stability and 
play an important role in carcinogenesis. A robust DNA repair capacity may lessen 




Numerous SNPs in DNA excision repair genes have been reported, and studies of 
these SNPs and prostate cancer risk will provide additional understanding of the 
etiology of prostate cancer. For example, the genetic variation in the BER gene APE1 
is found to be associated with prostate cancer risk in Brazilian men (172). XRCC1 
encodes a stimulator and scaffold protein for the BER pathway. It interacts with 
PARP1, DNA ligase III and DNA Pol ß, etc., as aforementioned.  Polymorphisms 
have been previously identified in XRCC1 that correlate with phenotypic changes 
(130). Although many SNPs have been discovered in XRCC1, only three have been 
investigated regarding prostate cancer risk, R194W, R280H, and R399Q. The 
XRCC1 R194W is indicated to have no association with prostate cancer risk in two 
small studies (173, 174), or to be protective in a Chinese population (175). The 
studies evaluating the XRCC1 R280H polymorphism have not produced any 
conclusive findings on its association with prostate cancer risk (174, 175). The 
XRCC1 R399Q polymorphism has been the most frequently investigated among the 
BER gene polymorphisms. It is significantly associated with prostate cancer risk in 
European Americans (176) and Asians (173, 175, 177), but not in African Americans 
(176), while other studies do not replicate the positive associations (177, 178). Low 
intake of antioxidants may modify the risk (174, 179). The human 8-Oxoguanine 
DNA Glycosylase 1 (hOGG1) catalyzes the excision and removal of single base 
adducts. The hOGG1 S326C polymorphism is reported to be associated with prostate 
cancer risk in Caucasian patients (180). Genetic polymorphisms in XRCC7 and 
XRCC3, genes in the non-homologous end-joining (NHEJ) and homologous 




high Gleason scores in North Indian populations (172). PARP1 V762A 
polymorphism is observed to have an increased risk of prostate cancer and a decrease 
in enzyme function in response to oxidative damage (135). 
The NER pathway is associated with the repair of bulky adducts induced by 
several suspected environmental prostate cancer carcinogens, such as polycyclic 
aromatic hydrocarbons, heterocyclic aromatic amines from well-done meats, and 
pesticides (181). Deficient NER capacity is found in lymphocytes from patients with 
prostate cancer (182). XPD D312N and K751Q are reported to have no association 
with prostate cancer in Caucasian and Chinese populations, but XPF R415Q is 
moderately associated with an increased risk of prostate cancer though not 
statistically significant (183-185). Additional studies on other NER genes, such as 
XPG, XPC and hR23B, do not observe positive association in the polymorphisms in 
these gene with prostate cancer risk (183).  
Efforts to identify prostate cancer susceptibility genes will be useful in 
understanding the etiology and molecular genetics of prostate cancer and hopefully in 
early detection of prostate cancer. 
3.2.2. Radiation therapy in Prostate Cancer  
Localized prostate cancer is treated by active monitoring, radical 
prostatectomy, or radiation therapy, depending on the tumor characteristics and the 
patient’s life expectancy. Radiation therapy is an important treatment option for 
patients with localized, early stage prostate cancer. In patients with T1 to T3 lesions, 




surgery (radical prostatectomy) or radiation therapy. Radiation therapy can be 
delivered by any of several approaches: external beam, brachytherapy, and intensity 
modulated radiation therapy (IMRT). However, with surgery or with radiation 
therapy, a percentage of patients with well-documented localized disease will 
experience the return of their malignancy.  
In patients with low risk localized prostate cancer, treated with modern IMRT, 
actuarial PSA relapse-free survival is 85% to 89%. In unfavorable risk localized 
prostate cancer, the actuarial PSA relapse-free survival is 59% to 72% (186). 
Therefore, even in the group of patients with the best clinical features and the most 
favorable prognosis, 11% to 15% of these patients have intra-tumor characteristics 
that lead to relapse of disease.  
Though considerable inter-patient differences in response to radiotherapy 
occur, the mechanisms behind these different responses are not well understood. A 
variety of patient, tumor, treatment, and molecular factors contribute to the various 
outcome of radiotherapy. The understanding of this mechanism may increase the 
predictability of outcome and selection of the optimal treatment. The work published 
by the Radiation Therapy Oncology Group (RTOG) investigated a total of 11 
potential prognostic markers, and only p53 and DNA ploidy showed association with 
overall survival (187). One question is whether there are intra-tumor considerations, 
such as DNA repair pathways, that may make some prostate cancer cells more 





3.2.3. Radiation and DNA excision repair 
Ionizing radiation acts through the creation of various types of DNA damage, 
the inter-individual DNA repair capacity may influence the patient’s radiosensitivity. 
The types of DNA damage induced by radiation include DNA base damage and both 
single- and double-strand DNA breaks (188). Such lesions, if inadequately repaired, 
can lead to cell death by lethal chromosomal aberrations or apoptosis, the desired 
outcome of radiation therapy. Multiple DNA repair pathways are involved to 
maintain the genomic integrity, and the homologous repair (HR) and non-
homologous end-joining (NHEJ), NER and BER pathways are thought to contribute 
heavily to remove the damage caused by ionizing radiation (71, 188). 
The genetic polymorphisms in DNA repair genes are believed to contribute to 
such inter-individual differences. One important polymorphism in XRCC1 is R194W, 
located in the linker region separating the NH2-terminal domain (NTD) from the 
central BRCT1 (BRCA1 C-terminus) domain, as illustrated in Figure 3-1. The linker 
region was also suggested to be a potential binding domain of several interactive 
proteins, and is rich in basic amino acids. The substitution of arginine to hydrophobic 
tryptophan may affect the protein binding efficiency. According to a review by 
Goode et al. (189), the R194W polymorphism was related to reduced risk of cancer, 
and this was confirmed by two later association studies (190, 191). However, another 
study showed a highly significant association (p=0.0005) of R194W with the 
increased risk of head and neck cancer in a Korean population (192). The possible 




be misleading and this polymorphism might not be directly associated, but linked to 
another relevant polymorphism in a haplotype (130). The XRCC1 R194W 
polymorphism is not associated with chromosome aberration frequencies in retired 
radiation workers and is not thought to influence the response to occupational 
exposure to radiation (193). The second XRCC1 polymorphism, R399Q, is a well-
studied SNP located in the BRCT1 domain, which is essential for PARP1 binding. 
Cells carrying this mutation have been shown to be defective in responding to both X-
ray radiation and UV light (194). Studies correlated the polymorphisms in XRCC1 
with either adverse effects (195) or protective effects resulting from radiotherapy 





Figure 3-1: Structure of XRCC1 domains and locations of the single nucleotide 
polymorphisms (SNPs) genotyped in this study.  
NTD: N-terminal domain, NLS: nuclear localization signal domain, BRCT: BRCA C-
terminus domain, CK2: Ck2 phosphorylation sites, modified from (130). 
 
PARP1, another important gene in DNA repair, assists by recruiting XRCC1 




methyl groups that in turn increases the distance between 762 and its closest neighbor 
in the active site. This steric change looses the binding of NAD+ and reduces the 
enzymatic activity nearly two fold (134). As a consequence, the variant enzyme may 
be less able to sense the damage in DNA and reduce the recruitment of XRCC1 and 
other proteins involved in the repair process. Since PARP1 also plays an important 
role in repairing radiation inflicted lesions, several PARP1 inhibitors have been tested 
in clinical trials to try to increase the effectiveness of ionizing radiation in the 
treatment of cancer (201-203). 
In addition to the BER, the NER pathway also plays a role in removing 
multiple types of DNA damage, including those caused by UV light and platinum-
containing chemotherapy agents. Important genes in the NER, ERCC1, and XPF, are 
essential for the 5’ incision into the DNA strand that releases bulky DNA lesions 
(146, 147). XPD is a 5’- 3’ helicase that participates in DNA strand separation prior 
to the 5’ incision step performed by the ERCC1-XPF heterodimer (108). Important 
genetic polymorphisms in these genes have also been described and studied 
extensively, as discussed before. 
Our previous study shows that the variant alleles of the polymorphic DNA 
excision repair genes have significantly higher frequencies in EAs compared to AAs, 
suggesting a mild reduction in DNA excision repair function in the EA population 
(204). The aim of this study is to investigate whether the DNA excision repair gene 
polymorphisms are related to prostate cancer risk and the outcome of radiation 




3.3. Materials and Methods 
3.3.1. Sample collection & DNA isolation 
Five hundred and thirteen patients with castrate-resistant prostate cancer 
(CRPC) were analyzed in this study. These include 284 patients who received 
external beam radiotherapy (XRT) and/or brachytherapy and 229 patients with the 
same disease that did not receive radiotherapy. All patients were Caucasians and were 
enrolled in an institutional review board–approved clinical trial within the intramural 
program of the National Cancer Institute, and were arbitrarily assigned a number in 
our database to protect confidentiality. Informed consent was obtained from all 
subjects before trial participation. The 152 male Caucasian control samples were the 
same as those used in chapter 2. All volunteers had signed informed consent to allow 
their samples to be used for genotyping, and none had a diagnosis of cancer. Genomic 
DNA was extracted from serum or white blood cell buffy coat layers of whole blood 
of patients using the UltraSens Virus Kit according to the manufacturer's instructions 
(Qiagen, Valencia, CA). 
3.3.2. Genotyping methods  
The genotyping methods are the same as those used in the study in Chapter 2.  
3.3.3. Statistical analysis  
Confidence intervals for the odds ratios of the distributions of individual 




were determined using the exact method. The probability of survival as a function of 
time since diagnosis was determined by the Kaplan-Meier method. The statistical 
significance of the differences in survival among the genotypes was determined by 
the log-rank test. All p-values are two-tailed. 
3.4. Results 
3.4.1. Polymorphisms in DNA excision repair genes are not 
associated with prostate cancer  
Five hundred and thirteen patients with CRPC were assayed for 5 
polymorphisms: ERCC1 N118N (500C>T), XPD K751Q (2282A>C), XRCC1 
R399Q (1301G>A), XRCC1 R194W (685C>T), and PARP1 V762A (2446T>C).  
The distribution of these SNPs among the 513 patients studied was compared to the 
152 healthy volunteer controls. Statistical analyses of the genotype prevalence for all 
five polymorphisms revealed no evidence of any differences between the two groups 
(Table 3-1). All of the genotype distributions were in Hardy-Weinberg equilibrium in 










Table 3-1: Distribution of polymorphisms among healthy controls and patients with 
CRPC. 
SNP Genotype Control* Patients OR 95% CI P Value 
ERCC1 CC 23 (0.21) 91 (0.21) Referent - - 
N118N CT 53 (0.49) 197 (0.46) 0.940 0.5426 to 1.627 0.8899 
(500C>T) TT 32 (0.30) 143 (0.33) 1.129 0.6218 to 2.052 0.7595 
XPD AA 49 (0.42) 186 (0.43) Referent - - 
K751Q AC 56 (0.47) 178 (0.42) 0.837 0.5419 to 1.294 0.4399 
(2282A>C) CC 13 (0.11) 64 (0.15) 1.297 0.6608 to 2.546 0.5129 
XRCC1 CC 120 (0.87) 402 (0.89) Referent - - 
R194W CT 17 (0.12) 43 (0.09) 0.755 0.4154 to 1.372 0.3399 
(685C>T) TT 1 (0.01) 7 (0.02) 2.090 0.2544 to 17.16 0.6893 
XRCC1 GG 49 (0.46) 145 (0.41) Referent - - 
R399Q AG 47 (0.44) 151 (0.43) 1.086 0.6850 to 1.721 0.8144 
(1301G>A) AA 10 (0.10) 56 (0.16) 1.892 0.8967 to 3.994 0.1248 
PARP1 TT 80 (0.67) 315 (0.70) Referent - - 
V762A CT 32 (0.27) 123 (0.27) 0.976 0.6163 to 1.546 0.9068 
(2446T>C) CC 7 (0.06) 15 (0.03) 0.544 0.2147 to 1.380 0.1873 
 
OR = odds ratio, CI = exact confidence interval. 
*Values are number (percentage). 
 
3.4.2. Polymorphisms in DNA excision repair genes are not 
associated with the median survival time in prostate cancer 
We determined whether the polymorphisms in DNA excision repair genes 
were associated with the median survival time in prostate cancer using the univariate 
method. None of the polymorphisms evaluated showed a trend toward an association 
with the median survival time individually. The results are shown in Table 3-2. 
Patients displayed similar median survival time regardless of what ERCC1 and XPD 




genotype of XRCC1 R399Q had the longest survival time of 11.12 years. Patients 
having either the heterozygous genotype of XRCC1 R194W or the variant genotype 
of PARP1 V762A had relatively short median survival time (6.52 and 5.88 years, 
respectively), though not statistically significant. 
Table 3-2: Median survival time comparison in all patients with CRPC according to 


















SNP Genotype Median survival time (years) 
ERCC1 CC 8.21 
N118N CT 7.84 
(500C>T) TT 8.33 
 P Value* 0.7622 
XPD AA 8.13 
K751Q AC 8.21 
(2282A>C) CC 7.155 
 P Value 0.9925 
XRCC1 GG 8.17 
R399Q AG 7.77 
(1301G>A) AA 11.12 
 P Value 0.5256 
XRCC1 CC 8.06 
R194W CT 6.52 
(685C>T) TT 9.22 
 P Value 0.5493 
PARP1 TT 8.17 
V762A CT 7.69 
(2446T>C) CC 5.88 




3.4.3. Polymorphisms in DNA excision repair genes are not 
associated with the median survival in radiation therapy in 
prostate cancer 
To determine whether the polymorphisms in DNA excision repair genes are 
associated with the outcome of radiation therapy for prostate cancer, we categorized 
patients into two groups according to whether they have received radiation therapy 
for their prostate cancer, i.e. a radiation group and a non-radiation group, and 
compared the survival times for each genotype group. However, we did not find any 
of the polymorphisms showing a trend toward an association with the median survival 
time in either of the two groups. The results are presented in Table 3-3. 
In general, the median survival time in the radiation group was longer than 
those of the non-radiation group. In both groups, individuals carrying the XRCC1 
R194W CT genotype only had shorter median survival time compared to the 
homozygous genotypes of CC or TT. While in patients with the AG genotype of 
XRCC1 R399Q had similar median survival time as that of the variant genotype AA 
in the radiation group, but in the non-radiation group, patients with the AG genotype 
had a much shorter median survival time than those with the AA genotype (5.41 and 
8.305 years, respectively). Patients carrying the variant genotype of PARP1 V762A 
polymorphism had a median survival time as long as 11.675 years compared to 3.9 
years in the non-radiation group (Table 3-3). However, none of the comparisons 





Table 3-3: Median survival time comparisons in patients who received radiation 
therapy for their prostate cancer and patients who did not according to their genotypes 









ERCC1 CC 9.72 6.915 
N118N CT 10.35 4.781 
(500C>T) TT 8.86 6.381 
 P Value* 0.9649 0.4028 
XPD AA 8.86 6.7 
K751Q AC 10.33 5.32 
(2282A>C) CC 9.22 4.15 
 P Value 0.9325 0.6019 
XRCC1 GG 9.22 5.88 
R399Q AG 10.41 5.41 
(1301G>A) AA 11.75 8.305 
 P Value 0.8456 0.6261 
XRCC1 CC 9.66 5.88 
R194W CT 6.81 4.24 
(685C>T) TT 9.22 10.595 
 P Value 0.3361 0.8515 
PARP1 TT 9.55 5.9 
V762A CT 8.82 4.985 
(2446T>C) CC 11.675 3.9 
 P Value 0.6805 0.0949 
 
3.5. Discussion 
The study presented here investigated the possible association between 
polymorphisms in the NER and BER DNA repair genes and clinical outcome of 
radiation therapy in patients with prostate cancer. First, all five SNPs assessed in this 




Second, none of the polymorphisms investigated here showed a significant trend 
toward an association with the median survival time in patients with prostate cancer, 
nor did they show any association with the median survival time in patients who 
received radiation therapy for their localized prostate cancer. Regarding the BER 
genes, neither the XRCC1 R399Q nor the XRCC1 R194W was associated with the 
median survival time individually.  
DNA excision repair is an important mechanism for maintaining genomic 
stability and to prevent accumulation of DNA damage. Epidemiologic studies of 
genetic polymorphisms in DNA excision repair genes may inform individual 
susceptibility and provide further understanding on molecular mechanisms of 
carcinogenesis. The XRCC1 polymorphisms are indicated to have no association with 
prostate cancer risk in several studies (173, 174, 179, 185) or to be associated with 
increased risk of prostate cancer among heavy smokers in Chinese population (175). 
The same confounding results are seen for the NER genes as well. Our study of 5 
polymorphisms in 4 genes involved in both the NER and the BER pathways did not 
reveal any associations between the polymorphic DNA excision repair genes and the 
risk of prostate cancer in a European American population (p>0.05). The current 
challenge is the validation of the functional impact of the genetic polymorphisms in 
these DNA excision repair genes that have been identified by epidemiological studies. 
Laboratory studies indicate that the variant genotype of XRCC1 R399Q is 
more sensitive to X-ray and UV-light than the other two genotypes within this codon 
(194). XRCC1 R399Q is located in the BRCT1 domain (Figure 3-1), a critical region 




site is involved in survival after methylation damage (205). It is suggested that the 
substitution of an arginine to glutamine may cause the loss of a secondary structure 
feature such as an alpha helix that is important for correct protein-protein interactions 
in the BRCT1 domain, thus compromising the DNA repair capability (206). A study 
showed that the number of variant alleles in APE1 D148Q and XRCC1 R399Q 
genotypes was significantly correlated with prolonged cell-cycle delay following 
ionizing radiation (IR), which resulted in IR hypersensitivity in breast cancer cases 
(207). Theoretically, the variant allele of the XRCC1 R399Q may impair the 
interaction between XRCC1 and other proteins, resulting in inefficient removal of 
radiation induced DNA damage and prolonged cell cycle arrest, which delivers 
favorable response to radiotherapy. However, the results from our study did not show 
any correlation between the XRCC1 R399Q genotypes and the survival time in the 
patients who received radiation therapy for their prostate cancer. 
The R194W polymorphism is located in a linker region (residues 158–310) 
between the NTD and the central BRCT domain of XRCC1 (Figure 3-1), enriched in 
basic amino acids. The high pI and overall positive charge of this region was 
suggested to have an important role in proper secondary structure formation (208). 
This domain is also the potential protein-binding domain for several interactive 
protein partners (PCNA, APE1, etc.) of the XRCC1 protein. The transition from the 
positively charged arginine to a hydrophobic tryptophan could affect binding and 
DNA repair efficiency. An in vitro study suggested that the presence of the variant 
allele of R194W might result in a damaging effect and an intolerant protein (130). We 




(1% in the healthy volunteers and 2% in the patient group). A previous study showed 
that the variant allele of R194W had higher frequency in radiation-sensitive breast 
cancer cases (OR 1.98, 95% CI 0.92–4.17) (209). But our study showed no 
association between the R194W genotypes and the survival time of radiation therapy. 
Though some epidemiological studies did suggest the variant allele of XRCC1 
R194W confers reduced cancer risk (189), others suggested vice versa (192). As 
suggested by another study (210), possessing more than 4 SNPs in DNA repair genes 
resulted in hypersensitivity to radiation in cells obtained from patients with cancer 
(p<0.001). Another study shows that the wild type allele G of R399Q along with the 
variant allele T of R194W, and the wild type allele of XRCC1 R280H had shorter 
overall survival than other haplotypes in patients with lung cancer that received 
radiotherapy (p=0.04) (200). Taken together, these results suggest that a complex 
intergenic interaction between the alleles of XRCC1 polymorphisms may exist. 
Due to the important role that PARP1 plays in DNA damage detecting and 
responding, PARP inhibitors have been actively investigated to enhance the cytotoxic 
effects of ionizing radiation and DNA-damaging chemotherapy regimens. However, 
our study did not find positive association between the PARP1 V762A genotypes and 
the outcome of radiation therapy in patients with prostate cancer. 
One shortcoming of this retrospective study is that the patients in the non-
radiation group usually had more severe malignancies and received therapies other 
than radiation. That may account for the shorter median survival time in this group in 
general. Therefore, the comparisons of the median survival time between each 




DNA excision repair pathways help to maintain genetic stability and prevent 
the development of cancer. However, they also represent a potential mechanism of 
resistance to DNA damaging chemotherapy and radiation therapy. The 
polymorphisms in DNA excision repair genes provide the genetic basis for various 
DNA excision repair capability. To identify radiosensitive cancer patients before 
treatment may allow tailored radiation therapy and improve effectiveness and reduce 
















4. The ERCC1 N118N polymorphism does not change 
cellular ERCC1 protein expression or platinum sensitivity 
4.1. Abstract 
Genetic polymorphisms in ERCC1 are thought to contribute to altered 
sensitivity to platinum-based chemotherapy in the clinic. Although ERCC1 N118N 
(500 C>T, rs11615) is the most studied polymorphism, the impact of this 
polymorphism on platinum-based chemotherapy remains unclear. This is the first 
study where the functional impact of ERCC1 N118N on gene expression and 
platinum sensitivity was explored. An ERCC1 deficient cell line, UV20, was 
transfected with the ERCC1 cDNA clone with either C or T allele and examined for 
the changes in ERCC1 transcription, translation and platinum sensitivity. Both 
ERCC1 mRNA and protein expression levels increased upon cisplatin treatment, and 
peaked at 4 hours post-treatment, however, there were no differences between the two 
alleles (p>0.05). Cells complemented with ERCC1 showed significantly higher 
survival proportion than the parental cell line following platinum exposure 
(P<0.0001), although no differences were observed between the cells transfected with 
the wild type or the polymorphic allele. These data suggest that N118N itself is not 
related to the phenotypic differences in ERCC1 expression or function, rather the 




4.2. Introduction  
4.2.1. ERCC1 in NER and Platinum-based chemotherapy  
ERCC1 has been highly conserved through evolution and is constitutively 
expressed in all tissues. Mutational analysis revealed that the N-terminus of ERCC1 
is poorly conserved and is dispensable for repair functions, whereas the C-terminus 
possesses a strongly conserved motif sharing sequence homology with many DNA 
repair proteins. Most missense mutations in the central region of the protein produce 
an unstable protein or complex (47). An ERCC1 deficient Chinese Hamster Ovary 
(CHO) cell line 43-3B has the full length ERCC1 mRNA but a mutation (V98E) in 
the coding region of XPA-binding domain so that the produced protein is unable to 
bind XPA (211), indicating the importance of the integrity of the central region in the 
normal functioning of ERCC1. Whether ERCC1 has functions other than DNA repair 
has yet to be clarified, but it is thought that ERCC1 is essential for life. Deletion or 
disruption of mouse ERCC1 gives rise to the accumulation of endogenously 
generated DNA interstrand cross-links and severe symptoms including postnatal 
growth failure, nuclear abnormalities, life-limiting liver and kidney disease and 
senescence (212-214). The CHO cell lines defective in ERCC1 display unique, 
extreme sensitivity to ultraviolet radiation and cross-linking agents (215-217). The 
patient described with human inherited ERCC1 deficiency has severe developmental 
failure and morphological features very similar to cerebro-oculo-facio-skeletal 
(COFS). Patient cells exhibit moderate hypersensitivity to UV irradiation, indicating 




Platinum-based chemotherapies have been widely used in the treatment of 
several solid malignancies since its discovery. The response of tumor cells to 
platinum-based drugs involves DNA repair mechanisms. DNA lesions caused by 
platinum compounds are mainly repaired by the NER pathway. It recognizes the 
DNA damage and excise the platinum-DNA adducts from the injured DNA strand. 
ERCC1 is one of the proteins that make up the NER complex and several studies 
have linked ERCC1 to platinum resistance in cell lines and in human cancers. It 
forms a heterodimeric protein complex with XPF to carry out the 5’ incision in the 
presence of a DNA lesion. Reduction of ERCC1 function may predispose people to 
cancer due to the inefficiency of DNA damage removal. However, improved response 
to DNA-damaging chemotherapy in those individuals is anticipated. Inter-individual 
differences are observed for ERCC1 protein expression levels and have been 
correlated to the outcome of platinum-based chemotherapies. In a study conducted in 
patients with non-small cell lung cancer, cisplatin-based adjuvant chemotherapy was 
beneficial to those with ERCC1-negative tumors. While in the patients who did not 
receive adjuvant chemotherapy, individuals with ERCC1-postive tumors had 
prolonged survival time compared to those have ERCC1-negative tumors (81). 
However, the genetic contribution behind the mechanism of variation in ERCC1 
expression has yet to be clarified. To date, more than 190 single nucleotide 
polymorphisms (SNPs) have been reported for ERCC1, most of which are located in 
intronic or untranslated regions. Missense mutations in ERCC1 are rare and not well 
studied; the only reported human case with ERCC1 missense mutations shows severe 




silent polymorphism in exon 4 (500 C>T in mRNA, N118N, rs11615) has been 
extensively studied and associated with altered outcome in platinum-based 
chemotherapy in multiple malignancies, as summarized in Table 1-1. However, these 
studies were performed in different tumor types, different therapeutic regimens, using 
different criteria to measure response or outcome, and most of them had small groups 
of patients. Therefore, the results generated a mixed clinic picture, which poses the 
challenge to the understanding of the functional consequences of this silent mutation. 
4.2.2. Implications of silent mutations 
Silent mutations do not alter amino acid sequence, and therefore they are not 
expected to change the function of the protein. However, increasing evidence 
supports that codons encode more information than merely amino acid sequences, 
contrary to the widely accepted concept that the information necessary to define the 
three-dimensional structure of a protein largely resides in its amino acid sequence. 
For example, a study shows that a naturally occurring rare silent mutation in the 
MDR1 gene affects the timing of co-translational folding and insertion of P- 
glycoprotein into the membrane, thereby altering the structural and functional 
properties of the gene product (219). In addition, the moving of ribosome on mRNA 
is not uniform. The rate of the traffic is primarily determined by the genetic code and 
the relative abundance of tRNA molecules surrounding the translational machinery. 
The translational speed slows down at the transition into secondary structure, and the 




slow translating regions can affect folding efficiency (220, 221). Finally, alternative 
mRNA splicing may also give rise to more than one protein from one mRNA. 
The residues from 96-214 form a deep V-shaped cleft on ERCC1 that is the 
binding site for XPA. The N118 residue is within the region 107-156 that makes 
critical contacts with XPA though N118 itself does not directly interact with XPA. 
Therefore, a perturbation in translation could affect the effective folding of the 
encoded protein, and consequently the proper function of the protein product. The 
two codons, AAC and AAT, which encode asparagine, have different usage 
frequencies (21.30 for AAC and 16.43 for AAT) according to “The human codon 
usage and codon preference table” (http://genome.crg.es/courses/ 
genefinding/T4/main/). 
Hence, to test if the silent mutation of ERCC1 N118N has phenotypic impact 
on gene expression and protein function, we introduced a ERCC1 cDNA clone with 
either C or T at the specific position into an ERCC1 deficient cell line UV20, denoted 
by UV20ERCC1_C and UV20ERCC1_T. We then assayed for ERCC1 mRNA and protein 
expression levels upon cisplatin treatment and the cellular sensitivity to platinum-
containing drugs. 
4.3. Materials and Methods 
4.3.1. Cell culture 
The ERCC1 deficient cell line UV20 was obtained from the American Type 




by mutagenizing the parental cell line AA-8 with EMS (222, 223). The ERCC1 gene 
in this cell line encodes a truncated protein that is barely detectable by Western blot 
(224). It is an ideal model for studying ERCC1 mutations. The cells were maintained 
in a humidified incubator at 37°C equilibrated with 5% CO2 and 95% air in Alpha 
minimum essential medium containing 10% fetal bovine serum and 1% Penicillin-
Streptomycin. To determine the minimum concentration of Geneticin®, 5 X 104 cells 
were plated in 6-well plates, and a range of Geneticin concentrations were tested. 750 
ug/ml of Geneticin was used to select the stable transfected cell line. The plasmids 
containing the reference or variant allele of ERCC1 N118N, as well as the vector 
control, were transfected into UV-20 cells using the Lipofectamine™ LTX Reagent 
according to the manufacurer’s instructions (Invitrogen, Carlsbad, CA). The stable 
transfected cell lines were designated as UV20ERCC1_C and UV20ERCC1_T, respectively. 
4.3.2. LR recombination reaction 
The ERCC1 Ultimate™ ORF clone (IOH5754, NM_001983) was purchased 
from Invitrogen. The plasmid was grown in competent E. coli and purified. Then the 
target gene was introduced into the expression vector pcDNA™3.2/V5-DEST by the 
LR recombination reaction (225): mix 150 ng of the entry clone and 150 ng of the 
destination vector (pcDNA™3.2/V5-DEST) with 4µl of 5X LR Clonase Reaction 
Buffer and TE buffer, bring to the final volume of 8 µl, then add 2 µl LR Clonase; 
incubate reactions at 25°C for 60 minutes; add 1 µl of the Proteinase K solution to 





Then, the LR reaction product was transformed into DH5α™ competent E. 
coli cells by the heat-shock method to amplify the plasmids. The transformed cells 
were selected by ampicillin. pUC19 DNA was used as the control plasmid for 
transfection efficiency. The plasmid DNA was purified using the QIAGEN® Plasmid 
Purification kit. The purified plasmid DNA containing the ERCC1 ORF clone then 
served as the template for the mutagenesis PCR. 
4.3.3. Site-directed mutagenesis 
The mutant was generated using the ERCC1 ORF clone in the pcDNA™/V5-
DEST vector as the template using the QuikChange® Lightning Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). The following primers were used in the 
mutagenesis PCR: 5’-ACT GAA GTT CGT GCG CAA TGT GCC CTG GG-3’ and 
Primer2: 5’-CCC AGG GCA CAT TGC GCA CGA ACT TCA GT-3’. The 
introduced allele is in italics. 50 ng of starting DNA template, PfuUltra HF (high 
fidelity) DNA polymerase and low number of thermal cycles (18 cycles) were used in 
the mutagenesis PCR to eliminate the unwanted second-site errors and obtain high 
mutation efficiencies. The thermal cycles included one heating step at 95°C for 2 
minutes in the beginning, 18 cycles of 95°C for 20 seconds, 60°C for 10 seconds, and 
68°C for 1.5 minutes/kb of plasmid length, followed by a final extension at 68°C for 
5 minutes. After the PCR, 1 µl Dpn I restriction enzyme was applied to the PCR 
product to digest the parental methylated or semimethylated DNA. The reaction was 
carried out by heating at 37°C for 10 minutes. Then the Dpn I-treated DNA was 




the protocol. The nicked vector DNA containing the desired mutations was fixed in 
the cells. The pWhitescript™ 4.5-kb control plasmid and the control primers were 
used to monitor the efficiency of mutant plasmid generation. 
The proper construction of both the original ORF clone and the synthesized 
mutant strand were verified by direct sequencing using the Big Dye Terminator Cycle 
Sequencing Ready Reaction kit V3.1 (Applied Biosystems, Foster City, CA) and an 
ABI Prism 3130 Genetic Analyzer using the manufacturers instructions.  
4.3.4. Real-time RT PCR 
Expression of ERCC1 mRNA was measured by quantitative reverse 
transcription-PCR (RT-PCR) using the Stratagene Mx3005P™ Real-Time PCR 
System. Briefly, cell lysates were collected at the appointed time following treatment 
of cisplatin (3.75×10-2 mg/ml) using AllPrep RNA/Protein Kit (Qiagen, Valencia, 
CA). Total RNA extracted was reverse-transcribed using the RT² First Strand Kits 
(SABiosciences, Frederick, MD). Each sample was analyzed in duplicate and the 
results are an average of four analyses. Analysis of mRNA expression was conducted 
using the RT² qPCR Primer Assay (PPH01539A, SABiosciences, Frederick, MD) for 
ERCC1 and normalized to the expression of CHO ACTB (226).  
4.3.5. Western blotting 
Expression of ERCC1 protein was assessed by Western blot analysis. Cells 
were washed in cold PBS and lysed in 100 µl of RIPA buffer (25 mM Tris-HCl pH 




µl/ml of Halt™ Protease Inhibitor Cocktail (Pierce) at 4°C. Samples were then 
sonicated on ice and collected by centrifuging at 14,000 × g for 15 minutes. Protein 
concentration was determined with BCA Protein Assay Kit (Pierce, Rockford, IL) 
and 20 µg of protein was subjected to electrophoresis on a NuPage® 4-12% Bis-Tris 
Gel (Invitrogen, Carlsbad, CA). Proteins were transferred electrophoretically to a 
PVDF membrane using the iBlot® Dry Blotting System (Invitrogen, Carlsbad, CA). 
The membrane was blocked in Odyssey blocking buffer (LI-COR, Lincoln, NE) 
followed by an overnight incubation with a 1: 200 dilution of ERCC1 primary 
antibody (FL-297, Santa Cruz Biotechnology, Santa Cruz, CA). For detection with 
the Odyssey imaging system, a 1: 5,000 dilution of the infrared fluorophore 
conjugated antibody, IRDye™ 800-conjugated goat anti-rabbit IgG was used. 
Proteins were visualized using the Odyssey Infrared Imaging System and Odyssey 
software (LI-COR, Lincoln, NE). Quantification of western blots was performed 
using ImageJ (http://rsbweb.nih.gov/ij/) according to the developer’s instructions.  
4.3.6. Cell cytotoxicity assays 
The night before treatment, cells were plated in 96-well plates at a density of 
5000 cells/well. A range of cisplatin (2.56×10-6 to 0.2 µg/µl), carboplatin and 
oxaliplatin concentrations (3.2×10-4 to 1 µg/µl) was tested in triplicate. Cells were 
exposed to these concentrations of toxicants for 1 hour and then incubated with fresh 
medium without toxicants for another 72 hours. Cell viability was tested using CCK-
8 (Dojindo, Rockville, MD) and CellTiter-Blue® (Promega Corporation, Madison, 




4.3.7. Statistical analysis 
Data are presented as the mean ± SD. To assess statistical significance of 
differences, Student's t test or one-way ANOVA was conducted. P values <0.05 were 
considered statistically significant. All statistical analyses were conducted using 
GraphPad Software (GraphPad Software, Inc., La Jolla, CA). 
4.4. Results  
4.4.1. ERCC1 expression in UV20 cell lines  
In order to compare the effects of the genetic polymorphism of ERCC1 
N118N (500 C>T) on ERCC1 expression and platinum sensitivity in the same genetic 
background, the ERCC1 deficient cell line UV20, a derivative from CHO cell line, 
was employed. The UV20 cell lines stably expressing ERCC1 with C or T allele, 
denoted by UV20ERCC1_C and UV20ERCC1_T, were established. ERCC1 protein 
expression levels in each cell were measured by western blot. As shown in Figure 4-
1, the parental UV20 cell line and the empty vector pcDNA™/V5-DEST transfected 
cells did not show detectable ERCC1 protein expression, while cells transfected with 
ERCC1 cDNA containing either genotype of 500 C>T showed comparable ERCC1 









Figure 4-1: ERCC1 protein expression levels in transfected UV20 cell lines are 
comparable.  
The UV20 cell lines stably expressing ERCC1 with C or T allele were established. 
ERCC1 protein expression levels in each cell were measured by western blot. The 
parental UV20 cell line and the empty vector pcDNA™/V5-DEST transfected cells 
(UV20VECTOR) did not show detectable ERCC1 protein expression, while cells 
transfected with ERCC1 cDNA containing either genotype of 500 C>T, UV20ERCC1_C 
and UV20ERCC1_T, showed comparable ERCC1 protein expression levels.  
4.4.2. Real-time quantitative PCR analysis reveals no difference in 
levels of ERCC1 transcripts in UV20ERCC1_C and UV20ERCC1_T 
cell lines 
To study how exogenous stress induces ERCC1 transcription in the 
transfected UV20 cell lines, we assayed for changes in ERCC1 mRNA expression 
levels upon cisplatin treatment in UV20 cells transfected C or T allele by quantitative 
RT-PCR. The basal levels of ERCC1 transcripts in UV20ERCC1_C and UV20ERCC1_T 
cell lines were similar, as normalized to beta-actin expression in each cell line 
(Figure 4-2). Upon cisplatin treatment, the expression levels of ERCC1 transcripts 
increased in both cell lines immediately. This increase peaked at 4 hours following 
cisplatin induction. However, there were no differences in ERCC1 transcript levels 




cisplatin treatment, the ERCC1 transcription level started to decrease. The two cell 
lines showed comparable levels of ERCC1 transcripts (p= 0.6376).  
 
Figure 4-2: The levels of ERCC1 transcripts in UV20ERCC1_C and UV20ERCC1_T cell 
lines remained the same upon cisplatin treatment.  
There was no difference in ERCC1 transcripts in the cells transfected with either C or 
T allele before treatment (p=0.495). ERCC1 transcription increased in both cell lines 
30 minutes after cisplatin treatment. This increase in transcription peaked at 4 hours 
following cisplatin induction. However, there was no significant difference in ERCC1 
gene expression levels between the two transfected cell lines, UV20ERCC1_C and 
UV20ERCC1_T (p=0.1737). Results are obtained from 4 independent experiments with 
duplicates in each experiment. 











































4.4.3. ERCC1 protein expression levels in UV-20 cells with 
different ERCC1 N118N (500 C>T) genotypes remained the 
same 
To investigate how the 500 C>T allele affects ERCC1 translation upon 
cisplatin induction, we used western blot analysis to examine ERCC1 protein levels 
in the UV20ERCC1_C and UV20ERCC1_T cell lines. Figure 4-3 shows that in both cell 
lines, ERCC1 protein expression levels increase upon cisplatin treatment, and peak at 
4 hours post-treatment, reaching a 2.28 fold increase in UV20ERCC1_C cell line and 
1.71 fold increase in UV20ERCC1_T cell line (p=0.5061).  This increase in protein 
production dropped after 24 hours. However, there was no significant difference in 
ERCC1 expression upon cisplatin challenge, although UV20ERCC1_C cell line did show 













Figure 4-3: ERCC1 expression levels in UV20ERCC1_C and UV20ERCC1_T cell lines 
following cisplatin treatment did not show difference.  
Upper panel: Western blots for ERCC1. Lower panel: Quantification of ERCC1 
expression change following cisplatin treatment. Data are mean ± SD obtained from 
three independent experiments. The expression levels of ERCC1 in the control cells 
pre-treatment were arbitrarily assigned 1. The change in ERCC1 level is expressed as 
the fold change compared to untreated cells. Data were normalized for equal loading. 
4.4.4. Cellular sensitivity to platinum compounds did not exhibit 
difference in UV20ERCC1_C and UV20ERCC1_T cell lines 
Lastly, cell viability assays were performed to determine if the cells 
transfected with different alleles of ERCC1 N118N would respond to platinum drugs 
differently. Both the UV20ERCC1_C and UV20ERCC1_T cells showed significantly 
increased viability upon cisplatin treatment compared to the parental cell line and 
vector transfected control cell line, as confirmed by CCK-8 and CellTiter-Blue assays 
independently (Figure 4-4, upper panel). The survival proportion of UV20ERCC1_C 
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and UV20ERCC1_T cells were not affected by cisplatin at the concentration of 3.2×10-4 
mg/ml. However, only 32% of the parental cell line and 47% of cells transfected with 
the empty vector survived after treated by 3.2×10-4 mg/ml of cisplatin (P<0.0001). 
When the cisplatin concentration was increased to 0.0016 mg/ml, 13% and 27% cells 
survived for the parental and control cell lines while 87% of UV20ERCC1_C cells and 
88% of UV20ERCC1_T cells survived, respectively (P<0.0001). Nonetheless, the 
UV20ERCC1_C and UV20ERCC1_T cell lines did not show differences in terms of 
cisplatin sensitivity. Similar results were obtained for carboplatin and oxaliplatin 
















Figure 4-4: Cell viability did not change in the UV20ERCC1_C and UV20ERCC1_T cell 
lines.  
The parental cell line UV20, empty vector transfected control cell line, and ERCC1 
cDNA with either allele of 500 C>T transfected cell line UV20ERCC1_C and 
UV20ERCC1_T were treated with cisplatin (0, 2.56×10-6, 6.40×10-5, 3.2×10-4, 1.6×10-3, 
8×10-2, 4×10-2, 0.2 µg/µl), carboplatin (0, 3.2×10-4, 1.6×10-3, 8×10-2, 4×10-2, 0.2 and 
1.00 µg/µl) and oxaliplatin (0, 3.2×10-4, 1.6×10-3, 8×10-2, 4×10-2, 0.2 and 1.00 µg/µl). 
The cell cytotoxicity was tested by CCK-8 and CellTiter-Blue assayes. Only the 
results from CCK-8 assay for carboplatin and oxaliplatin are shown. Data are mean ± 
SD obtained from three independent experiments with triplicates in each experiment. 
4.5. Discussion  
Personalized medicine is the use of both a patient’s genotypic and phenotypic 
data to choose a treatment or therapy that will best help the patient by maximizing 
benefit and minimizing harm (227). Therefore, it is important to understand how the 
inter-individual variations in the DNA sequence of specific genes affect drug 
responses. By introducing the cDNA clone of ERCC1 containing either C or T allele 
of N118N into an ERCC1 deficient cell line UV20, we examined the functional 
consequences of the genetic polymorphisms on ERCC1 expression and function. We 
found that this polymorphism did not contribute to altered ERCC1 expression upon 
cisplatin treatment or cellular sensitivity to platinum-containing drugs in vitro.  
The ERCC1 N118N silent mutation was first described by genotyping a series 
of human cell lines and ovarian cancer tumor tissue specimens, and it was suggested 
that the conversion of the common codon AAC to an infrequently used codon AAT 




suggested that this polymorphism could affect the DNA repair capacity in human 
ovarian cancer cell lines through a reduction in peak ERCC1 mRNA production and a 
consequent reduction in the translation of ERCC1 mRNA into protein (164). A 
growing body of literature shows that ERCC1 expression level correlates with 
response to platinum containing reagents (81, 228-231) while the results of genetic 
association studies are not always consistent (Table 1-1). The codon usage frequency 
for the SNP at position 500 with AAC changed to AAT (both encode Asn) changes 
moderately from 21.30 to 16.43 per thousand. This codon usage preference is 
conserved among species.  
To test whether the synonymous codons of AAC and AAT in exon 4 of 
ERCC1 affects gene expression and function in response to platinum drugs, we 
established UV20 cell lines constitutively expressing ERCC1 with C or T allele at the 
500 position in the mRNA, named UV20ERCC1_C and UV20ERCC1_T. Our results 
showed that the two cell lines had close basal ERCC1 transcription levels and 
performed similarly in ERCC1 transcription upon cisplatin induction. The 
UV20ERCC1_C cells showed slightly faster production of ERCC1 protein than the 
UV20ERCC1_T cells that corresponds to the moderate codon usage bias toward the 
AAC codon. However, it did not reach statistical significance. Nonetheless, the 
UV20ERCC1_C and UV20ERCC1_T cell lines exhibited the same level of sensitivity to 
platinum-containing drugs, including cisplatin, carboplatin and oxaliplatin.  
The amino acid asparagine at this position is conserved among species, 
however, the wild type allele at the third position of this codon is not conserved, 




(http://genome.ucsc.edu). Some species use AAC, such as rhesus, dog and opossum, 
etc., while others use AAT, such as human, mouse, elephant and zebrafish, etc. In 
addition, this SNP ERCC1 N118N (rs11615) is not under selective pressure in 
European, African or Chinese decent as indicated by low positive Tajima’s D values 
(232, 233). These results confirm that this SNP has little to no phenotypic effects 
although there is a clear preference for asparagine at the 118th amino acid. 
Furthermore, the LD (linkage disequilibrium) plot shows that this SNP is linked in a 
haplotype block of 18 KB within ERCC1 and the adjacent genomic region in 
European population. But this is not true for African or Asian populations (234). 
Although another NER gene, ERCC2 (also called XPD), is located in the same 
chromosome, the haplotype block does not extend to ERCC2 in any of the three 
populations, suggesting linkage disequilibrium with causative SNPs within ERCC1 
might account for previous clinical associations with ERCC1 N118N. Mutations in 
ERCC1 that cause protein sequence change are not common and the only reported 
case is an infant possessing two point mutations that has severe developmental 
abnormality and does not thrive (218). Therefore, instead of focusing on the ERCC1 
N118N polymorphism, future genetic association studies should be expanded to 
include other polymorphisms linked to ERCC1 N118N, such as those in the 








5. ERCC1 polymorphisms are associated with melanoma  
5.1. Abstract 
Reduced DNA repair capacity has been proposed as a risk factor for skin 
melanoma. The incidence of skin melanoma is 20 times higher in European 
Americans (EAs) than in African Americans (AAs). And in fact, increased 
frequencies of DNA repair gene polymorphisms have also been found in EAs 
compared to AAs. Here we evaluated 6 genetic polymorphisms in 4 DNA excision 
repair genes in relation to skin melanoma risk. 165 patients with malignant skin 
melanoma were screened, as well as 156 EA and 164 AA healthy controls. The 
polymorphism N118N in ERCC1 that showed a significant association with 
melanoma (p=0.0047) was further investigated and our data revealed that it was 
linked to two other polymorphisms in a nearby intron; and the haplotypes of these 
ERCC1 polymorphisms are associated with skin melanoma by significant margins. 
Carrying the variant haplotype allele or not carrying the wild type haplotype allele 
significantly increased risk of melanoma (p=0.0034 and p=0.0011, respectively). The 
variant haplotype allele of ERCC1 confers melanoma risk in an additive and recessive 
way. AAs have significantly fewer melanoma risky alleles (p<0.0001). EAs have a 
higher genetic risk of getting skin melanoma than AAs based on our study of ERCC1 
polymorphisms. However, when the fusion genes containing either the wild type or 




melanoma cell line, they did not exhibit any differences in the transcriptional levels, 
suggesting that these alleles may not be causal. 
5.2. Introduction 
5.2.1. NER deficiency and skin cancer 
Cancer development requires the accumulation of numerous genetic 
alterations that are usually believed to occur through the presence of compromised 
DNA repair machinery. The NER pathway is the most versatile and best-studied 
DNA repair pathway in humans. NER can repair a variety of bulky DNA damage, 
including UV-light induced DNA photoproducts. It is believed that at least 11 NER 
genes are involved in more than 8 clinical syndromes (235). However, the 
relationship between the genetic defects in the NER genes and the clinical diseases is 
complex. NER deficiencies result in profound photosensitivity and at least three 
autosomal recessive disorders: xeroderma pigmentosum (XP), Cockayne syndrome 
(CS) and trichothiodystrophy (TTD). NER-defective XP can be classified into 7 
complementation groups, XPA to XPG. XP is known to be associated with mutations 
in the XP genes, ERCC1 and POLH (Polymerase eta), while mutations in XPA and 
XPC account for approximately 50% of XP (235). XP is characterized by serious UV 
sensitivity, a strong disposition to skin cancers and, in severe cases, 
neurodegeneration. TC-NER is defective in Cockayne syndrome, which is 
characterized by UV sensitivity, short stature, neurodisability, dysmorphic features, 




which is also characterized by UV sensitivity, in addition to brittle hair and scaling of 
skin (237, 238). However, TTD and CS patients have normal skin cancer risk (239).  
In addition, COFS syndrome is a recessively inherited rapidly progressive neurologic 
disorder which shares clinical similarities with CS. Deficiencies in NER genes have 
also been proposed as causes for COFS (240).  
The estimated incidence of skin cancer is elevated more than 1000-fold in 
individuals with XP. Cells from XP patients exhibit inability to repair UV damage to 
their DNA (141). This results in the accumulation of mutations in the DNA of skin 
cells after exposure to sunlight, which eventually leads to enhanced mutational 
burden in cells and neoplastic transformation.  
5.2.2. ERCC1 and skin melanoma 
Basal cell carcinoma and squamous cell carcinoma are the two most common 
forms of skin cancer and are together referred to as the nonmelanoma skin cancer, 
whereas melanoma is the most lethal form of skin cancer, and is characterized by 
therapeutic resistance and predisposition for metastasis. Substantial epidemiological 
evidence suggests that hair-color and freckling, as indirect measurements of the skin’s 
reaction to sun, family history, age and the number of raised nevi are the risk factors 
of malignant melanoma. Overexposure to sun is generally thought to increase the risk 
of melanoma. Solar UV light, the major environmental carcinogen, is absorbed in 
DNA and results in the formation of pyrimidine dimers. Nucleotide excision repair is 




(119). Inefficient repair of DNA damage can result in cancerous transformation of the 
cells, as aforementioned.  
Cumulative evidence has suggested the importance of DNA excision repair 
mechanism in the etiology of melanoma. Previous case-control studies indicated that 
variations in NER genes, including ERCC1, XPF and XPD, are associated with an 
increased risk of melanoma (241-243). Using host cell reactivation assay to evaluate 
the repair of UV-induced DNA damages, Wei et al. showed that cells from patients 
with melanoma had significantly lower DNA repair capacity than control cells (244). 
Another study has shown that mice with skin-specific ERCC1 deficiency are 
hypersensitive to UV irradiation (245).  
The incidence of melanoma is 20 times higher in European Americans than in 
African Americans (http://www.cdc.gov/cancer/npcr/uscs/pdf/2002_USCS.pdf). The 
variant genotypes in DNA repair genes, including ERCC1 and XPD in the NER 
pathway and XRCC1 and PARP1 in the BER pathway, were found to be significantly 
more prevalent in European Americans, compared to African Americans (Table 2-3). 
This is thought to be associated with a reduction in DNA excision repair capability 
and thus a possibly better response to DNA damaging chemotherapy in European 
American patients (204). Therefore, we hypothesize that the polymorphisms in DNA 
excision repair genes that have different allelic distributions between African and 
European populations may be responsible for the increased risk to melanoma. In this 
study, we investigated the association between the DNA excision repair genes and 
melanoma. Furthermore, we focused on 4 polymorphisms in ERCC1 that have 




SNP database, in both melanoma cases and healthy controls. The haplotypes 
identified by the association analysis were then fused with reporter genes and 
transfected to a skin melanoma cell line, and their effects on transcription were 
examined.  
5.3. Materials and Methods 
5.3.1. Genotyping methods 
320 whole blood samples from healthy male volunteers were the same as 
those used in the previous study in chapter 2.   
165 patients with malignant melanoma were analyzed. All patients were EAs 
and were enrolled in an institutional review board–approved clinical trial within the 
intramural program of the National Cancer Institute, and were arbitrarily assigned a 
number in our database to protect confidentiality. Informed consent was obtained 
from all subjects before trial participation.  
The genotyping methods are described in details in Chapter 2. The genotyping 
method for ERCC1 N118N is the same as used in Chapter 2 and 3. The PCR primers 
and conditions used for ERCC1 rs3212948, rs3212950 and rs3212929 are listed in 









Table 5-1: Primers and PCR conditions for ERCC1 polymorphisms. 
5.3.2. Statistical analysis 
Haploview (234) was used to calculate allele frequencies for the investigated 
ERCC1 polymorphisms from the data. Haploview software was also used to perform 
linkage disequilibrium assessment and to define the haplotype blocks by the 
incorporated confidence interval method (246). The standard chi-squared statistics 
was also used for association test and Hardy-Weinberg Equilibrium test. 
5.3.3. Cell culture 
SK-Mel-5 cell line was obtained from American Type Culture Collection 
(Manassas, VA). The cells were maintained in a humidified incubator at 37°C 
equilibrated with 5% CO2 and 95% air in RPMI-1640 medium containing 10% fetal 
bovine serum and 1% Penicillin-Streptomycin. 
5.3.4. Plasmid constructs and transfection 
The gene fragments containing ERCC1 intron 3 and exon 4 regions were 
amplified from patients with melanoma that have either homozygous wild type or 
SNPs Primers Size (bp) 
Annealing 
Temp (°C) 
FW 5’- AGG AGA GAC GCC CAA CCA GG-3’ rs3212948 
and 
rs3212950 RE 5’- TGG CAC CAG GCC TTT CCT AAA G-3’ 
576 66 °C 
FW 5’- TCA GAG AGC TGC AAG TTA GAA CAG 
TG-3’ rs3212929 
T>G RE 5’- TTG ACT TGG CTT CAG TTT CCT C -3’ 




homozygous variant haplotypes as defined in the association analysis. The PCR 
products were cloned in-frame between the EcoRI and KpnI sites of the pCMV-HA 
and pCMV-Myc vector set. The vector pair was co-transfected into SK-Mel-5 cells 
using Lipofectamine™ 2000 (Invitrogen, CA) when cells were 70 % confluent per 
manufacturer’s instructions. 
5.3.5. RNA isolation and RT–PCR 
Expression of HA or Myc-tagged ERCC1 fragments were measured by 
quantitative reverse transcription-PCR (RT-PCR) using the Stratagene Mx3005P™ 
Real-Time PCR System (La Jolla, CA). Briefly, cells were lysed and the total RNA 
was collected 48 hours after transfection using the RNeasy Mini Kit (Qiagen, 
Valencia, CA). Total RNA extracted was reverse-transcribed using RT² First Strand 
Kits (SABiosciences, Frederick, MD). Each sample was analyzed in duplicate and the 
results are an average of four analyses. Analysis of mRNA expression was conducted 
using primers specific to the tag and the ERCC1 sequence, and normalized to a 
human housekeeping gene GAPDH by RT² qPCR Primer Assay (SABiosciences, 
Frederick, MD).  
5.4. Results 
5.4.1. DNA excision repair genes and melanoma 
First we genotyped the patients with melanoma for the DNA excision repair 
gene polymorphisms as investigated in the previous study in Chapter 2, and compared 




polymorphisms, only ERCC1 N118N (rs11615) was found to be associated with 
melanoma (Table 5-2). Therefore, we focused our future studies on polymorphisms 
within the ERCC1 gene. 
Table 5-2: Allele distribution of DNA excision repair genes in patients with 








OD (95% CI) P 
C 99 (0.46) 104 (0.33) 
T 117 (0.54) 208 (0.67) 
ERCC1 
N118N 
(500C>T) TOTAL 216 312 
1.692 
(1.185 to 2.417) 0.0047 
C 213 (0.73) 73 (0.79) 
A 79 (0.27) 19 (0.21) ERCC1 C8092A TOTAL 292 92 
0.701751 
(0.398 to 1.237) 0.2193 
A 154 (0.65) 36 (0.67) 
C 82 (0.35) 18 (0.33) 
XPD 
K751Q 
(2282A>C) TOTAL 236 54 
0.939024 
(0.502 to 1.756) 0.8438 
G 145 (0.68) 60 (0.64) 
A 67 (0.32) 34 (0.36) 
XRCC1 
R399Q 
(1301G>A) TOTAL 212 94 
1.22637 
(0.736 to 2.044) 0.4332 
C 257 (0.93) 86 (0.96) 
T 19 (0.07) 4 (0.04) 
XRCC1 
R194W 
(685C>T) TOTAL 276 90 
0.629131 
(0.2084 to 1.901) 0.4076 
T 192 (0.81) 78 (0.85) 
C 46 (0.19) 14 (0.15) 
PARP1 
V762A 
(2446T>C) TOTAL 238 92 
0.749164 
(0.390 to 1.440) 0.3854 
 
5.4.2. Allele distribution of ERCC1 polymorphisms  
 In this study, the DNA samples from 165 European American patients with 
skin melanoma, 156 healthy individuals of European American descent, and 164 
healthy individuals of African American descent were genotyped for 4 SNPs in the 




rs3212950 (C>G) and rs3212948 (G>C) in intron 3, and rs3212929 (T>G) in the 5’ 
utr. All the SNPs analyzed were in Hardy-Weinberg Equilibrium, except rs3212929, 
which showed Hardy-Weinberg disequilibrium in AA population (p=0.0021) with a 
lower observed heterozygosity (0.33) than expected (0.483). 
The allele frequencies in patients with melanoma and EA and AA healthy 
individuals are summarized below. Patients with melanoma carry more variant alleles 
T, G, C, G of rs11615, rs3212950, rs3212948 and rs3212929 than controls (Table 5-
3), and African Americans carry fewer melanoma risk alleles than European 
Americans by a strongly significant margin (p<0.0001, Table 5-4).  
Table 5-3: Distribution of ERCC1 alleles in patients with melanoma and European 
American (EA) healthy controls. 






(freq.)) OR (95%CI) P value 
T 196(0.681) 105(0.553) 
rs11615 
C 92(0.319) 85(0.447) 
1.73 (1.18 - 2.52) 0.0051 
G 201(0.698) 107(0.563) 
rs3212950 
C 87(0.302) 83(0.437) 
1.79 (1.22 - 2.62) 0.0033 
C 202(0.701) 104(0.547) 
rs3212948 
G 86(0.299) 86(0.453) 
1.94 (1.33 - 2.84) 0.0007 
G 287(0.997) 183(0.963) 
rs3212929 
T 1(0.003) 7(0.037) 









Table 5-4: Distribution of ERCC1 alleles in African American (AA) and European 
American (EA) populations. 




(freq.)) OR (95%CI) P value 
C 180(0.874) 85(0.447) rs11615 T 26(0.126) 105(0.553) 
8.55 (5.18 - 
14.11) P<0.0001 
C 168(0.816) 83(0.437) rs3212950 
G 38(0.184) 107(0.563) 
5.70 (3.62 - 8.98) P<0.0001 
G 168(0.816) 86(0.453) rs3212948 C 38(0.184) 104(0.547) 5.35 (3.40 - 8.41) P<0.0001 
T 84(0.408) 7(0.037) rs3212929 G 122(0.592) 183(0.963) 
18.00 (8.05 - 
40.24) P<0.0001 
5.4.3. Haplotype and diplotype reconstruction and association 
analysis 
To determine whether specific ERCC1 alleles might be associated with 
melanoma, and therefore overrepresented in the patient group, haplotypes were 
derived using Haploview. The pairwise r2 values in patients with melanoma, EA and 
AA healthy volunteers are shown in Table 5-5. Three SNPs, including rs11615, 
rs3212950 and rs3212948 were defined in one haplotype block. Three common 
haplotypes were identified: homozygous variant TGC, homozygous wild type CCG 
and heterozygous CGC. The diplotypes were estimated based on the haplotype 








Table 5-5: Pairwise r2 in patients with melanoma, EA and AA healthy volunteers. 
r^2 
L1 L2 Patients with 
melanoma EA controls AA controls 
rs11615 rs3212950 0.86 0.916 0.515 
rs11615 rs3212948 0.876 0.895 0.515 
rs11615 rs3212929 0.007 0.021 0.099 
rs3212950 rs3212948 0.984 0.938 1 
rs3212950 rs3212929 0.008 0.022 0.083 
rs3212948 rs3212929 0.008 0.02 0.083 
 
Table 5-6: Haplotypes (upper) and diplotype reconstruction (lower). 
Haplotype 










(G>C) Patients with melanoma EA controls 
TGC T G C 194 (0.674) 
102 
(0.536) 
CCG C C G 85 (0.295) 
82 
(0.431) 




 Patients with melanoma EA controls 
DIPLOTYPE Counts Freq. Counts Freq. 
TGC-TGC 69 0.486 27 0.294 
TGC-CCG 50 0.352 45 0.489 
CCG-CCG 16 0.113 18 0.196 
TGC-CGC 5 0.035 1 0.011 
CCG-CGC 2 0.014 1 0.011 
 
By comparing the haplotype allele frequencies, we observed that patients with 
melanoma carried the variant haplotype allele TGC at a much higher frequency than 




CCG at a significantly lower frequency than controls (30% vs. 45%, p=0.0011), 
shown in Table 5-7.  The comparison between AAs and EAs showed that the AAs 
carried TGC at a significantly lower frequency than EAs (12% vs. 54%, p<0.0001), 
and carried the CCG haplotype at a much higher frequency than EAs (83% vs. 45%, 
p<0.0001). The individuals with missing genotypes or rare haplotypes were excluded 
in further analysis.  
Table 5-7: Association analysis of ERCC1 haplotype allele frequencies in patients 






(Counts (freq.)) OR (95%CI) P Value 
Carries TGC 193 (0.68) 100 (0.54) 
Does not carry TGC 91 (0.32) 84 (0.46) 
1.782 (1.215 - 2.612) 0.0034 
Does not carry CCG 200 (0.70) 102 (0.55) 
Carries CCG 84 (0.30) 82 (0.45) 
1.914 (1.300 - 2.818) 0.0011 
Carries CGC 7 (0.02) 2 (0.01) 
Does not carry CGC 277 (0.98) 182 (0.99) 
2.3 (0.4723 - 11.20) 0.493 
 
Diplotype analysis showed that 52% of patients with melanoma had a 
diplotype without the wild type allele CCG, while only 30% of healthy controls had a 
diplotype without the wild type allele (OR=2.487, p=0.0024). However, whether the 
individuals had a diplotype with or without the variant allele TGC did not show 




















Does not carry 
CCG 74 (0.52) 28 (0.30) 
Carries CCG 68 (0.48) 64 (0.70) 
2.487 (1.431 - 
4.324) 0.0024 
Carries TGC 124 (0.87) 73 (0.79) 
Does not carry 
TGC 18 (0.13) 19 (0.21) 
1.793 (0.8844 
- 3.635) 0.2828 
 
To examine which genotype has a greater effect on melanoma risk, not 
carrying the wild type CCG allele or carrying the variant TGC allele, we then 
compared the frequencies of individuals having two copies CCG, TGC-CCG, and two 
copies TGC in the patient groups and the control group. 11% of patients with 
melanoma had the homozygous wild type diplotype CCG-CCG, while its frequency is 
doubled (20%) in the healthy controls. The heterozygous diplotype TGC-CCG did not 
show a significant association with melanoma risk, however, carrying two copies of 
the variant TGC allele significantly increased the individual’s risk of getting 


















OR (95%CI) P Value 
CCG-CCG 16 (0.11) 18 (0.20) 1.0 (N/A) N/A 
TGC-CCG 50 (0.35) 45 (0.49) 1.25 (0.5702 - 2.740) 0.6899 
TGC-TGC 69 (0.49) 27 (0.29) 2.875 (1.282 - 6.445) 0.0119 
 
The same comparison was made between the EA and the AA populations, and 
the results showed that the AA individuals carried the TGC-TGC diplotype at a 
frequency as low as 1%, while 66% of them had the homozygous wild type CCG-
CCG (p<0.001). 
5.4.4. Effect of ERCC1 haplotypes on transcripts abundance 
In order to determine if the haplotypes identified in the association study are 
causal, the homozygous wild type and variant haplotypes CCG-CCG and TGC-TGC 
of ERCC1 intron 3 and exon 4 were cloned in-frame between the EcoRI and KpnI 
sites of the pCMV-HA and pCMV-Myc vector set. The plasmids were transiently 
transfected into a skin melanoma cell line, SK-Mel-5, and the relative transcripts 
levels of the fusion genes were measured the quantitative RT-PCR. The level of 
transcripts of the wild type fusion gene was 1.16 fold higher than the variant genotype 






Figure 5-1: Relative abundance of transcripts of the two fusion genes with wild type 
or variant genotypes. 
 
5.5. Discussion 
Melanoma is the most dangerous type of skin cancer. According to American 
Academy of Dermatology, it is the leading cause of death from skin cancer, 
accounting for 75% of all skin cancer deaths, and one American dies from melanoma 
almost every hour. Overexposure to the UV component of sunlight is an established 
risk factor for developing skin cancer. The incidence of skin melanoma is surprisingly 
higher in the European American population than in African Americans. 
Pigmentation is generally thought to be a protective factor for African Americans. 
However, a recent study found that the variant polymorphisms of DNA excision 
repair genes are significantly more prevalent in European Americans, which may 
indicate a relatively lower DNA excision repair capacity in the respective repair 
















maintaining genomic integrity. Reduction in DNA repair capacity is thought to be 
responsible for increased risk for several types of cancer (71). Despite the high 
penetrance of NER deficiency in XP patients, little is known about the correlations of 
the common genetic polymorphisms in DNA excision repair genes and risk of skin 
melanoma. Many DNA repair gene polymorphisms have been investigated in terms 
of genetic predisposition to skin melanoma, and positive associations were found for 
XPF (243) and XPD (241, 242, 249). In addition, the wild type ERCC1 
polymorphism was found to be associated with melanoma in patients under 50 (243).  
In this study, we investigated genetic polymorphisms in DNA excision repair 
genes in relation to skin melanoma. Only the ERCC1 N118N polymorphism showed 
significant association with melanoma among the 6 DNA excision repair gene 
polymorphisms. ERCC1 is a gene essential to life and plays multiple roles in addition 
to its function in the NER pathway, such as in recombination repair and some 
unknown processes (218). When extended to more SNPs in ERCC1 that have 
different allelic distributions in African and European populations, a haplotype was 
identified and showed a strong correlation with risk of skin melanoma. Two SNPs in 
intron 3 are in linkage with the N118N polymorphism in exon 4. The variant 
haplotype has a significantly higher frequency in patients with melanoma, while the 
variant haplotype has a protective effect toward the risk of skin melanoma. The 
homozygous variant diplotype of ERCC1 associates with increased risk of skin 
melanoma but not the heterozygous diplotype, suggesting that the ERCC1 
polymorphisms behave additively and recessively. African Americans carry 




type or variant diplotype of ERCC1 did not show differences in transcriptional levels 
when transiently expressed in a skin melanoma cell line.  
Based on our study, European Americans have an increased genetic risk for 
skin melanoma than African Americans. The melanoma risky ERCC1 alleles 
identified in this study may not be causal. This association could be due to the 
relatively high frequencies of the investigated polymorphisms in population or their 
linkage with causal alleles. It should be kept in mind that haplotype analysis may 
increase power to detect rare casual alleles but may decrease power to detect common 
causal alleles (250). The haplotype block extends to an 18 KB region including part 
of ERCC1 and the neighboring genome. The linkage patterns of ERCC1 and the 
surrounding genomic regions are different in African and Asian populations. Further 
work on fine mapping and on functional characterization of the polymorphisms in 
ERCC1 and linked regions is required.  
In addition, two recent genome-wide association studies identified several 
melanoma risk chromosomal loci, including 16q24 encompassing melanocortin-1 
receptor, 11q14-q21 encompassing tyrosinase, which are associated with well-
recognized melanoma risk factors such as pigmentation, freckling and cutaneous sun 
sensitivity, 9p21 (247) and 20q11 (248), which may contain common polymorphisms 
associated with melanoma. These studies were both done in melanoma high-risk 
populations, i.e., Europeans and Australians. These melanoma risk regions may have 






6. Summaries and future directions 
The human DNA excision repair mechanisms are complex and interweaving, 
and act as double-edged swords in cancer and cancer therapy. The goal of our study 
was directed towards increasing our understanding of the translational aspects of the 
DNA excision repair genes. Cancer therapies that cause cytotoxicity by damaging 
DNA, such as platinum-based drugs and radiation therapy, are useful in clinical 
oncology. However, these therapeutic regimens also have severe side effects and can 
be carcinogenic as well. Therefore, being able to assess who would benefit from such 
therapies would be useful and would allow the avoidance of unnecessary toxicity to 
those who would be predicted to have no benefit.  
Pharmacogenetics is a fast-evolving field in oncology. Ideally, it will allow 
physicians to use a patient’s genotypic and phenotypic data to choose a treatment that 
will best help the patient by maximizing benefit and minimizing harm (227). To 
achieve this goal, a thorough and extensive understanding of the genetic composition 
and the biological consequences is necessary. In this study, we assessed the genetic 
polymorphisms in the DNA excision repair pathways in the context of cancer and 
cancer therapies causing DNA damaging.  
In addition to inter-individual variation in drug response, there are also 
observed inter-population differences in the outcome of certain chemotherapies that 
have been widely used, such as platinum-based chemotherapies. In general, the 
mortality rate is higher in African American patients in malignancies where these 




be due to a variety of reasons, such as differences in patient access to medical care 
and/or medical care delivery. It is also likely that these differences are the results of 
patients’ response to the same therapies. In our investigation of the genetic 
polymorphisms of DNA excision repair genes involved in the molecular mechanisms 
of DNA-damaging chemotherapies, we found that a population difference in the 
genetic makeup generally exists in these genes. The genetic polymorphisms that we 
assessed in this study include ERCC1 N118N (500C>T), ERCC1 C8092A, XPD 
K751Q (2282A>C) from the NER pathway, and XRCC1 R399Q (1301G>A), 
XRCC1 R194W (685C>T) and PARP1 V762A (2446T>C) from the BER pathway. 
Significantly higher frequencies of the genetic variants of the assessed genes were 
found to occur in European Americans, as compared to African Americans. This may 
imply a moderate reduction in the repair capabilities of the respective pathways in 
European Americans, thereby leading to a better outcome once DNA-damaging 
chemotherapies are used this population. 
DNA damage and repair is far broader and deeper than we used to think, 
especially in our understanding and successful treatment of cancer. The most widely 
used class of anticancer compounds is the platinum-containing agents. Radiation is 
also critically important in treating various early stage diseases. Although both 
therapeutic methods are useful, they are also toxic. Therefore, being able to stratify 
patients by genetic or molecular markers for efficacy and/or toxicity will be 
extremely helpful. In order to understand if these genetic polymorphisms also 
contribute to the outcome of radiation therapy, we investigated the aforementioned 




summarized in chapter 3. Firstly, we compared the distributions of these DNA 
excision repair gene polymorphisms between patients with prostate cancer and the 
healthy controls that were assessed in chapter 2. However, we found that the genetic 
polymorphisms in DNA excision repair genes are not associated with risk of prostate 
cancer. Secondly, we assessed whether the above-mentioned DNA excision repair 
gene polymorphisms were correlated to the outcome of radiation therapy in patients 
with prostate cancer. Our results indicated that none of these polymorphisms showed 
an association toward the overall survival of radiation therapy in prostate cancer. 
As reviewed in previous chapters, genetic association studies on the DNA 
excision repair genes and cancer and DNA-damaging cancer therapies have generated 
confusing results. This is partly due to the limitations of such studies including 
limited sample sizes, mixed cancer types and treatment regimens, accuracy and 
consistency of diagnostic criteria, as well as the tendency of both the investigators 
and the journals to report positive results. Consequently, the literature has become 
weighted toward unconfirmed associations. This is especially true for the ERCC1 
N118N polymorphism, one of the most important genetic markers for platinum-based 
chemotherapies, as summarized in chapter 1. Therefore, in the following study 
presented in chapter 4, we investigated the biological consequences of this 
synonymous mutation N118N in ERCC1 in a well-controlled in vitro system. By 
introducing the human ERCC1 cDNA clones with either the wild type or the variant 
genotype of the N118N polymorphism into an ERCC1 deficient CHO cell line, we 
were able to test the two alleles’ effects on ERCC1 gene transcription, translation and 




polymorphism did not differ in the biological consequences that we assayed. 
Therefore, we believe that any observed association between this polymorphism and 
the outcome of platinum-based chemotherapies is most likely due to its linkage with 
other polymorphisms in ERCC1. This hypothesis led to our next investigation, which 
was aimed at looking for the possible causal genetic polymorphisms for ERCC1 
function.  
DNA damage and repair is also important in the etiology of skin melanoma, 
which is the most lethal form of skin cancer. DNA damage induced by UV irradiation 
is mainly removed through DNA excision repair mechanisms. The incidence of 
melanoma is 20 times higher in European Americans than in African Americans. Skin 
tone is usually thought to be a protective factor for African Americans. However, we 
found that the genetic variants of DNA excision repair gene rarely occur in this 
population. Rather, the frequencies of these variant DNA excision repair gene 
polymorphisms are significantly higher in European Americans, as shown in chapter 
2. Hence, the causal genetic polymorphisms for reduced DNA excision repair 
functions might also show an association toward skin melanoma. Subsequently, we 
found that haplotypes in ERCC1 that are associated with skin melanoma, as reported 
in chapter 5. The wild type alleles of ERCC1 polymorphisms had protective effects 
toward skin melanoma; the variant alleles work in an additive and recessive fashion. 
In addition, European Americans have a higher genetic risk of getting melanoma than 
African Americans, based on the results of our study. However, the functional 
analysis did not reveal any differences in transcriptional levels of the fusion genes 




identified haplotypes in ERCC1 might be associated with skin melanoma but not 
causal for ERCC1 functional changes.  
Intrinsic or acquired resistance to DNA-damaging chemotherapy is widely 
observed, and the mechanisms underlying this have been extensively investigated but 
not fully defined. Varied levels of ERCC1 protein expression were found in the tumor 
specimens from patients with NSCLC, and were associated with the outcome of 
platinum-based adjuvant chemotherapy (81). However, it would be helpful to be able 
to predict ERCC1 protein expression levels without taking tissues samples from a 
patient before administering platinum-based chemotherapies. This causes a thorough 
understanding of the genetic polymorphisms of this gene. As discussed in chapters 4 
and 5, the LD plot shows a haplotype block of 18 KB within ERCC1 and the adjacent 
genomic region in European. Therefore, the causal SNPs in ERCC1 may be located in 
the linked region, and are worth investigating. However, using the HapMap data may 
result in missing the uncommon polymorphisms since only 90 individuals were 
sequenced in each population by the HapMap project. Hence, sequencing and 
comparisons of the entire ERCC1 gene in individuals with a known response to 
platinum-based chemotherapies would greatly advance our knowledge about this 
gene in the context of platinum sensitivity. Additionally, the biological consequences 
of such polymorphisms should also be assessed before too many association studies 
are conducted. On top of that, genome wide association studies could also be 
performed, taking advantage of the high-throughput genotyping methods, to locate 
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